Поиск
Закладки
Озвучить текст Озвучить книгу
Изменить режим чтения
Изменить размер шрифта
Оглавление
Для озвучивания и цитирования книги перейдите в режим постраничного просмотра.
Артериальная гипертензия у взрослых

Список литературы

  1. Rosenberg WM, Gray JA et al. Evidence based medicine: what it is and what it isn"t. BMJ 1996, January; 312 (7023): 71–72..
  2. Федеральный закон от 21.11.2011 № 323-ФЗ (ред. от 03.04.2017) «Об основах охраны здоровья граждан в Российской Федерации».
  3. Эпидемиологический словарь, 4-е издание. Под ред. Джона М. Ласта для Международной эпидемиологической ассоциации. М., 2009. 316 с..
  4. Федеральное агентство по техническому регулированию и метрологии. Национальный стандарт Российской Федерации. ГОСТР 52379-2005. Надлежащая клиническая практика. Москва, 2005.
  5. Федеральный закон от 12.04.2010 № 61-ФЗ (ред. от 14.07.2022 N 311-ФЗ)) «Об обращении лекарственных средств»..
  6. Jansen RW, Lipsitz LA. Postprandial hypotension: epidemiology, pathophysiology, and clinical management. Ann Int Med 1995;122(4):286–295.
  7. Малая медицинская энциклопедия. М.: Медицинская энциклопедия, 1991—96 гг. [Электронный ресурс]. Режим доступа:http://dic.academic.ru/dic.nsf/enc_medicine/28878/Синдром.
  8. Общероссийская общественная организация «Российская ассоциация геронтологов и гериатров». Клинические рекомендации «Старческая астения». 2020., https://cr.minzdrav.gov.ru/recomend/613_1.
  9. Андреева Н. С., Реброва О. Ю., Зорин Н. А. и др. Системы оценки достоверности научных доказательств и убедительности рекомендаций: сравнительная характеристика и перспективы унификации. Медицинские технологии. Оценка и выбор. 2012. №. 4. С. 10–24..
  10. Rapsomaniki E et al. Blood pressure and incidence of twelve cardiovascular diseases: lifetime risks, healthy life-years lost, and age-specific associations in 1• 25 million people. The Lancet 383.9932 (2014):1899–1911..
  11. Ehret GB, Caulfield MJ. Genes for blood pressure: an opportunity to understand hypertension. Eur Heart J 2013;34:951–961..
  12. «2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension Endorsed by the European Renal Association (ERA),» and the International Society of Hypertension (ISH). Journal of Hypertension ():10.1097/HJH.0000000000003480, June 21, 2023. | DOI: 10.1097/HJH.0000000000003480.
  13. Elliott P, Stamler J, Nichols R, et al. Intersalt revisited: further analyses of 24 hour sodium excretion and blood . pressure within and across populations. Intersalt Cooperative Research Group. . BMJ 1996;312:1249–1253..
  14. «Guo Y, Li X, Wang Z, Yu B. Gut Microbiota Dysbiosis in Human Hypertension: A Systematic Review of Observational Studies. Front Cardiovasc Med. 2021;8:650227».
  15. «Wilck N, Matus MG, Kearney SM, et al. Salt-responsive gut commensal modulates TH17 axis and disease.».
  16. «Griendling KK, Camargo LL, Rios FJ, et al. Oxidative stress and hypertension. Circ Res 2021; 128:993–1020.».
  17. Кушаковский М. С. Эссенциальная гипертензия (гипертоническая болезнь). Причины, механизмы, клиника, лечение. СПб., 2002..
  18. Ланг Г. Ф. Гипертоническая болезнь. М.: Медгиз, 1950. 459 с..
  19. Постнов Ю. В., Орлов С. Н. Первичная гипертензия как патология клеточных мембран. М.: Медицина, 1987. 192 с..
  20. Мясников А. Л. Гипертоническая болезнь. М.: Медгиз, 1954..
  21. «Page IH. Pathogenesis of arterial hypertension. J Am Med Assoc 1949; 140:451–458.».
  22. Распространенность факторов риска неинфекционных заболеваний в российской популяции в 2012–2013 гг. Результаты исследования ЭССЕ-РФ. Кардиоваскулярная терапия и профилактика 2014; 13(6):4–11..
  23. Бойцов С. А., Баланова Ю. А., Шальнова С. А., Деев А. Д. и др. Артериальная гипертония среди лиц 25–64 лет: распространенность, осведомленность, лечение и контроль. По материалам исследования ЭССЕ. Кардиоваскулярная терапия и профилактика. 2014;4:4-14..
  24. Kearney PM, Whelton M, Reynolds K, et al. Global burden of hypertension: analysis of worldwide data. Lancet 2005;365:217–223..
  25. Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants. NCD Risk Factor Collaboration (NCD-RisC)., Lancet 2021; 398: 957–80. doi:10.1016/ S0140-6736(21) 01330-1..
  26. Franklin SS, Lopez VA, Wong ND, et al. Single versus combined blood pressure components and risk for cardiovascular disease: the Framingham Heart Study. Circulation 2009;119:243–250..
  27. Williams B, Mancia G, Spiering W et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension:, The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. JHypertens 2018;36(10):1953–2041..
  28. Lewington S, Clarke R, Qizilbash N et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002;360:1903–1913..
  29. Lip GYH, Coca A, Kahan T, et al. Hypertension and cardiac arrhythmias: executive summary of a consensus document from the European Heart Rhythm Association (EHRA) and ESC Council on Hypertension, endorsed by the Heart Rhythm Society (HRS),, Asia-Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulacion Cardiaca y Electrofisiologia (SOLEACE). Eur Heart J Cardiovasc Pharmacother 2017;3:235–250..
  30. Gottesman RF, Albert MS, Alonso A, et al. Associations between midlife vascular risk factors and 25-year incident dementia in the Atherosclerosis Risk in Communities (ARIC) cohort. JAMA Neurol 2017;74:1246–1254..
  31. Rovio SP, Pahkala K, Nevalainen J et al. Cardiovascular risk factors from childhood and midlife cognitive performance: the Young Finns study. J Am Coll Cardiol 2017;69:2279–2289..
  32. Vishram JK, Borglykke A, Andreasen AH, et al, MORGAM Project. Impact of age on the importance of systolic and diastolic blood pressures for stroke risk: the MOnica, Risk, Genetics, Archiving, and Monograph (MORGAM) project. Hypertension 2012;60:1117–1123.
  33. Brown DW, Giles WH, Greenlund KJ. Blood pressure parameters and risk of fatal stroke, NHANES II mortality study. Am J Hypertens 2007;20:338–341..
  34. Franklin SS, Khan SA, Wong ND, et al. Is pulse pressure useful in predicting risk for coronary heart disease? The Framingham heart study. Circulation 1999;100:354–360..
  35. Domanski M, Mitchell G, Pfeffer M, Neaton JD, Norman J, Svendsen K, Grimm R, Cohen J, Stamler J, MRFIT Research Group. Pulse pressure and cardiovascular disease-related mortality: follow-up study of the Multiple Risk Factor Intervention Trial (MRFIT)., JAMA 2002;287:2677–2683..
  36. Кобалава Ж. Д., Конради А. О., Недогода С. В. и др. Меморандум экспертов Российского кардиологического общества по рекомендациям Европейского общества кардиологов/Европейского общества по артериальной гипертензии по лечению артериальной гипертензии, 2018 г. Российский кардиологический журнал. 2018;(12):131–42..
  37. Reino-Gonzalez S. et al. How in-office and ambulatory BP monitoring compare: A systematic review and meta-analysis. – 2017..
  38. Kollias A., Ntineri A., Stergiou G. S. Association of night-time home blood pressure with night-time ambulatory blood pressure and target-organ damage: a systematic review and meta-analysis //Journal of hypertension. – 2017. – Т. 35. – №. 3. – С. 442-452..
  39. Fagard RH, Celis H, Thijs L, et al. Daytime and night-time blood pressure as predictors of death and cause-specific cardiovascular events in hypertension. Hypertension 2008; 51:55–61..
  40. Ward AM, Takahashi O, Stevens R, Heneghan C. Home measurement of blood pressure and cardiovascular disease: systematic review and meta-analysis of prospective studies. J Hypertens 2012; 30:449–456..
  41. Mancia G, Facchetti R, Bombelli M, et al. Long-term risk of mortality associated with selective and combined elevation in office, home and ambulatory blood pressure. Hypertension 2006; 47:846–853..
  42. Fagard RH, Cornelissen VA. Incidence of cardiovascular events in white-coat, masked and sustained hypertension vs. true normotension: a meta-analysis. J Hypertens 2007; 25:2193–219..
  43. Rimoldi SF, Scherrer U, Messerli FH. Secondary arterial hypertension: when, who, and how to screen? Eur Heart J 2014;35:1245–1254..
  44. Carey RM, Calhoun DA, Bakris GL. Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association. Hypertension. 2018 Nov;72(5):e53-e90..
  45. Noubiap JJ, Nansseu JR, Nyaga UF et al. Global prevalence of resistant hypertension: a meta-analysis of data from 3.2 million patients Heart 2019;105:98–105..
  46. Albasri A. et al. A comparison of blood pressure in community pharmacies with ambulatory, home and general practitioner office readings: systematic review and meta-analysis //Journal of hypertension. – 2017. – Т. 35. – №. 10. – С. 1919..
  47. Sega R, Facchetti R, Bombelli M, et al.Prognostic value of ambulatory and home blood pressures compared with office blood pressure in the general population: follow-up results from the Pressioni Arteriose Monitorate e Loro Associazioni (PAMELA) study., Circulation 2005;111:1777–1783..
  48. «Stergiou GS, Palatini P, Parati G, et al., European Society of Hypertension Council and the European Society of Hypertension Working Group on Blood Pressure Monitoring and Cardiovascular Variability.,» 2021 European Society of Hypertension practice guidelines for office and out-of-office blood pressure measurement. J Hypertens 2021; 39:1293–1302. .
  49. «Stergiou GS, Mukkamala R, Avolio A, et al., European Society of Hypertension Working Group on Blood Pressure Monitoring and Cardiovascular Variability. Cuffless blood pressure measuring devices:,» review and statement by the European Society of Hypertension Working Group on Blood Pressure Monitoring and Cardiovascular Variability. J Hypertens 2022; 40:1449–1460. .
  50. Clark CE, Taylor RS, Shore AC, et al. Association of a difference in systolic blood pressure between arms with vascular disease and mortality: a systematic review and meta-analysis. Lancet 2012;379:905–914..
  51. Tucker KL, Sheppard JP, Stevens R et al. Self-monitoring of blood pressure in hypertension: a systematic review and individual patient data meta-analysis. PLoS Med 2017;14:e1002389..
  52. «Yang WY, Melgarejo JD, Thijs Let al., International Database on Ambulatory Blood Pressure in Relation to Cardiovascular Outcomes (IDACO) Investigators. Association of office and ambulatory blood pressure with mortality and cardiovascular outcomes.,» JAMA 2019; 322:409–420..
  53. «Fujiwara T, Hoshide S, Kanegae H, Kario K. Cardiovascular event risks associated with masked nocturnal hypertension defined by home blood pressure monitoring in the J-HOP Nocturnal Blood Pressure Study. Hypertension 2020; 76:259–266.».
  54. «Stergiou GS, Palatini P, Parati G, et al., European Society of Hypertension Council and the European Society of Hypertension Working Group on Blood Pressure Monitoring and Cardiovascular Variability. 2021 European Society of Hypertension practice,» guidelines for office and out-of-office blood pressure measurement. J Hypertens 2021; 39:1293–1302..
  55. «Parati G, Bilo G, Kollias A, et al. Blood pressure variability: methodological aspects, clinical relevance and practical indications for management - a European Society of Hypertension position paper 0. J Hypertens 2023; 41:527–544.».
  56. «Wang N, Harris K, Hamet P, , et al. Cumulative systolic blood pressure load and cardiovascular risk in patients with diabetes. J Am Coll Cardiol 2022; 80:1147–1155.».
  57. «Mahfoud F, Mancia G, Schmieder RE, et al. Cardiovascular risk reduction after renal denervation according to time in therapeutic systolic blood pressure range. J Am Coll Cardiol 2022; 80:1871–1880.».
  58. «Cheng YB, Thijs L, Aparicio LS, et al. Risk stratification by cross-classification of central and brachial systolic blood pressure. Hypertension 2022; 79:1101–1111.».
  59. «Sharman JE, Avolio AP, Baulmann J, et al. Validation of noninvasive central blood pressure devices: ARTERY Society task force consensus statement on protocol standardization. Eur Heart J 2017; 38:2805–2812».
  60. «Palatini P, Rosei EA, Avolio A, et al. Isolated systolic hypertension in the young: a position paper endorsed by the European Society of Hypertension. J Hypertens. 2018;36(6):1222-1236. doi: 10.1097/HJH.0000000000001726».
  61. «Kario K. Orthostatic hypertension-a new haemodynamic cardiovascular risk factor. Nat Rev Nephrol 2013; 9:726–738.».
  62. «Kostis WJ, Sargsyan D, Mekkaoui C, et al. Association of orthostatic hypertension with mortality in the Systolic Hypertension in the Elderly Program. J Hum Hypertens 2019; 33:735–740.».
  63. «Dani M, Dirksen A, Taraborrelli P, et al. Orthostatic hypotension in older people: considerations, diagnosis and management. Clin Med (Lond) 2021; 21:e275–e282.».
  64. SCORE2-OP working group and ESC Cardiovascular risk collaboration, SCORE2-OP risk prediction algorithms: estimating incident cardiovascular event risk in older persons in four geographical risk regions,, European Heart Journal, Volume 42, Issue 25, 1 July 2021, Pages 2455–2467, https://doi.org/10.1093/eurheartj/ehab312..
  65. SCORE2 working group and ESC Cardiovascular risk collaboration, SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe,, European Heart Journal, Volume 42, Issue 25, 1 July 2021, Pages 2439–2454, https://doi.org/10.1093/eurheartj/ehab309..
  66. Sehestedt T, Jeppesen J, Hansen TW, et al. Risk prediction is improved by adding markers of subclinical organ damage to SCORE. Eur Heart J 2010;31:883–891..
  67. Smart NA, Dieberg G, Ladhani M, Titus T. Early referral to specialist nephrology services for preventing the progression to end-stage kidney disease. Cochrane Database Syst Rev 2014;(6):CD007333. doi: 10.1002/14651858.CD007333.pub2.
  68. Black C, Sharma P, Scotland G et al. Early referral strategies for management of people with markers of renal disease: a systematic review of the evidence of clinical effectiveness, cost-effectiveness and economic analysis., Health Technol Assess 2010;14(21):1-184. doi: 10.3310/hta14210 .
  69. Chan MR, Dall AT, Fletcher KE et al. Outcomes in patients with chronic kidney disease referred late to nephrologists: a meta-analysis. Am J Med 2007;120(12):1063-70. doi: 10.1016/j.amjmed.2007.04.024.
  70. Hunt SC, Williams RR, Barlow GK. A comparison of positive family history definitions for defining risk of future disease. J Chronic Dis 1986; 39:809–821..
  71. Friedman GD, Selby JV, Quesenberry CP Jr, et al Precursors of essential hypertension: body weight, alcohol and salt use and parental history of hypertension. Prev Med 1988;17:387–402..
  72. Shi Y. et al. Resting heart rate and the risk of hypertension and heart failure: a dose–response meta-analysis of prospective studies //Journal of hypertension. – 2018. – Т. 36. – №. 5. – С. 995-1004..
  73. «Алгоритмы специализированной медицинской помощи больным сахарным диабетом / Под редакцией И.И. Дедова, М.В. Шестаковой, А.Ю. Майорова. – 10-й выпуск – М.; 2021.DOI: 10.14341/DM12802».
  74. «КР290. Сахарный диабет 2 типа у взрослых, Общественная организация «Российская ассоциация эндокринологов», 2022г. [Электронный ресурс https://cr.minzdrav.gov.ru/recomend/290_2 ].».
  75. Cosentino F, Grant P, Aboyans V et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: The Task Force for diabetes, pre-diabetes, and cardiovascular diseases of the, European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD). Eur Heart J 2019.
  76. Emerging Risk Factors Collaboration. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. The Lancet 375.9733 (2010): 2215–2222..
  77. Wilson PW, Cupples CF, Kannel WB. Is hyperglycemia associated with cardiovascular disease? The Framingham Study. Amer. Heart J 1991;121:586–90..
  78. Izzo R, de Simone G, Trimarco V. et al. Hypertensive target organ damage predicts incident diabetes mellitus. EurHeartJ. epub 27 June 2013..
  79. Matsushita K. et al. Comparison of risk prediction using the CKD-EPI equation and the MDRD study equation for estimated glomerular filtration rate //Jama. – 2012. – Т. 307. – №. 18. – С. 1941-1951..
  80. De Haan M. W. et al. Renovascular disease in patients with hypertension: detection with duplex ultrasound //Journal of human hypertension. – 2002. – Т. 16. – №. 7. – С. 501..
  81. Mahmoodi, Bakhtawar K., et al. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without hypertension: a meta-analysis. The Lancet 380.9854 (2012):1649–1661..
  82. Van Der Velde M. et al. Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts. Kidney international 79.12 (2011): 1341–52.
  83. Earley A, Miskulin D, Lamb EJ et al. Estimating equations for glomerular filtration rate in the era of creatinine standardization: a systematic review. Ann Intern Med 2012; 156: 785–795..
  84. Zachrisson K. et al. Duplex ultrasound for identifying renal artery stenosis: direct criteria re-evaluated //Acta Radiologica. – 2017. – Т. 58. – №. 2. – С. 176-182..
  85. Matsushita K. et al. Kidney measures beyond traditional risk factors for cardiovascular prediction: A collaborative meta-analysis //The lancet. Diabetes & endocrinology. – 2015. – Т. 3. – №. 7. – С. 514..
  86. Gerstein HC, Mann JF, Yi Q, Zinman B, et al. HOPE Study Investigators. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 2001;286:421–426..
  87. Boekholdt SM et al. Association of LDL cholesterol, non–HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis //Jama. — 2012. — Т. 307. — №. 12. — С. 1302-1309..
  88. Caggiula A. W. et al. The multiple risk factor intervention trial (MRFIT): IV. Intervention on blood lipids //Preventive Medicine. – 1981. – Т. 10. – №. 4. – С. 443-475..
  89. Prospective Studies Collaboration et al. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55 000 vascular deaths //The Lancet. – 2007. – Т. 370. – №. 9602. – С. 1.
  90. Geleijnse JM, Kok FJ, Grobbee DE. Blood pressure response to changes in sodium and potassium intake: a metaregression analysis of randomised trials. Journal of human hypertension 17.7(2003):471..
  91. Macdonald JE, Struthers AD. hat is the optimal serum potassium level in cardiovascular patients? Journal of the American College of Cardiology 43.2 (2004):155–161..
  92. Wang J. et al. Hyperuricemia and risk of incident hypertension: a systematic review and meta-analysis of observational studies //PloS one. – 2014. – Т. 9. – №. 12. – С. e114259..
  93. Grayson PC et al. Hyperuricemia and incident hypertension: a systematic review and meta‐analysis.. Arthritis care & research 63.1 (2011):102–110..
  94. Palmer TM et al. Association of plasma uric acid with ischaemic heart disease and blood pressure: mendelian randomisation analysis of two large cohorts. Bmj 347 (2013): f4262..
  95. Lehtonen AO, Puukka P, Varis J et al. Prevalence and prognosis of ECG abnormalities in normotensive and hypertensive individuals. J Hypertens 2016;34:959–966..
  96. Vanezis, A. P., & Bhopal, R. (2008). Validity of electrocardiographic classification of left ventricular hypertrophy across adult ethnic groups with echocardiography as a standard. Journal of Electrocardiology, 41(5), 404–412., doi:10.1016/j.jelectrocard.2008.02.013.
  97. Schillaci, G., Battista, F., & Pucci, G. (2012). A review of the role of electrocardiography in the diagnosis of left ventricular hypertrophy in hypertension. Journal of electrocardiology, 45(6), 617–623..
  98. Kahn S, Frishman WH, Weissman S et al. Left ventricular hypertrophy on electrocardiogram: prognostic implications from a 10-year cohort study of older subjects: a report from the Bronx Longitudinal Aging Study. J Am Geriatr Soc 1996;44:524–529..
  99. Okin PM, Devereux RB, Jern S, et al. LIFE Study Investigators. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events. JAMA 2004;292:2343–2349..
  100. Verdecchia P, Angeli F, Borgioni C. et al. Changes in cardiovascular risk by reduction of left ventricular mass in hypertension: a meta-analysis. American Journal of Hypertension. 2003. 16(11), 895–899..
  101. Sundstrom J, Lind L, Arnlov J et al. Echocardiographic and electrocardiographic diagnoses of left ventricular hypertrophy predict mortality independently of each other in a population of elderly men. Circulation 2001;103:2346–51..
  102. Levy D, Garrison RJ, Savage DO et al. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990;322:1561–6..
  103. Perrone-Filardi P, Coca A, Galderisi M et al. Non-invasive cardiovascular imaging for evaluating subclinical target organ damage in hypertensive patients: a consensus paper from the European Association of Cardiovascular Imaging (EACVI),, the European Society of Cardiology Council on Hypertension, and the European Society of Hypertension (ESH). Eur Heart J Cardiovasc Imaging 2017;18:945–960..
  104. «Spittell, Peter C., et al. "Screening for abdominal aortic aneurysm during transthoracic echocardiography in a hypertensive patient population." Journal of the American Society of Echocardiography 10.7 (1997): 722-727.».
  105. «Aboyans, Victor, et al. "Screening abdominal aorta aneurysm during echocardiography: literature review and proposal for a French nationwide study." Archives of cardiovascular diseases 103.10 (2010): 552-558.».
  106. «Shukha, Yousef, et al. "Screening of Abdominal Aortic Aneurysm Using Portable Transthoracic Echocardiography among Patients with Acute Coronary Syndrome." Cardiology Research and Practice 2020 (2020).».
  107. «Park, Hyung-Bok. "Clinical Usefulness of Additional Screening for Abdominal Aortic Aneurysm during Transthoracic Echocardiography." Journal of Cardiovascular Imaging 28.4 (2020): 265.».
  108. Jahromi A. S. et al. Sensitivity and specificity of color duplex ultrasound measurement in the estimation of internal carotid artery stenosis: a systematic review and meta-analysis //Journal of vascular surgery. – 2005. – Т. 41. – №. 6. – С. 962-972..
  109. Mourad J. J. et al. Screening of unrecognized peripheral arterial disease (PAD) using ankle-brachial index in high cardiovascular risk patients free from symptomatic PAD //Journal of vascular surgery. – 2009. – Т. 50. – №. 3. – С. 572-580..
  110. Vlachopoulos, C., Aznaouridis, K., Terentes-Printzios, D., Ioakeimidis, N., & Stefanadis, C. (2012). Prediction of Cardiovascular Events and All-Cause Mortality With Brachial-Ankle Elasticity Index: A Systematic Review and Meta-Analysis., Hypertension, 60(2), 556–562..
  111. Fuchs F. D. et al. Study of the usefulness of optic fundi examination of patients with hypertension in a clinical setting //Journal of human hypertension. – 1995. – Т. 9. – №. 7. – С. 547-551..
  112. Breslin DJ, Gifford RW Jr, Fairbairn JF II, Kearns TP. Prognostic importance of ophthalmoscopic findings in essential hypertension. JAMA 1966;195:335–338..
  113. Dimmitt SB, West JN, Eames SM et al. Usefulness of ophthalmoscopy in mild to moderate hypertension. Lancet 1989;1:1103–1106..
  114. White P. M., Wardlaw J. M., Easton V. Can noninvasive imaging accurately depict intracranial aneurysms? A systematic review //Radiology. – 2000. – Т. 217. – №. 2. – С. 361-370..
  115. Beynon R. et al. Is MRI better than CT for detecting a vascular component to dementia? A systematic review and meta-analysis //BMC neurology. – 2012. – Т. 12. – №. 1. – С. 33..
  116. Creavin S. T. et al. Mini‐Mental State Examination (MMSE) for the detection of dementia in clinically unevaluated people aged 65 and over in community and primary care populations //Cochrane Database of Systematic Reviews. – 2016. – №. 1..
  117. Tsoi KK, Chan JY, Hirai HW, et al. Cognitive tests to detect dementia: a systematic review and meta-analysis. JAMA Intern Med 2015;175:1450–1458..
  118. Mach F, Baigent C, Catapano A et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC), and European Atherosclerosis Society (EAS). Eur Heart J 2019.
  119. Ebrahim, S., & Smith, G. D. (1998). Lowering blood pressure: a systematic review of sustained effects of non-pharmacological interventions. Journal of Public Health, 20(4), 441–448..
  120. Ettehad D, Emdin CA, Kiran A, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet 2016;387:957–967..
  121. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension: 7. Effects of more vs. less intensive blood pressure lowering and different achieved blood pressure levels — updated overview and meta-analyses, of randomized trials. J Hypertens 2016;34:613–622..
  122. «Thomopoulos C. Target blood pressure in isolated systolic hypertension. A meta-analysis of randomized outcome trials. J Hypertens 2023;[in press].».
  123. Beckett NS, Peters R, Fletcher AE et al. HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008;358:1887–1898..
  124. Thijs, Lutgarde, et al. A meta-analysis of outcome trials in elderly hypertensives. Journal of hypertension 10.10 (1992): 1103–1109..
  125. Lonn EM, Bosch J, Lopez-Jaramillo P et al. HOPE-3 Investigators. Blood-pressure lowering in. intermediate-risk persons without cardiovascular disease. N Engl J Med. 2016;374:2009–2020.
  126. Agarwal R et al. Role of home blood pressure monitoring in overcoming therapeutic inertia and improving hypertension control: a systematic review and meta-analysis. Hypertension 57.1 (2011): 29–38..
  127. Sundstrom J, Arima H, Jackson R, et al. Blood Pressure-Lowering Treatment Trialists’ Collaboration. Effects of blood pressure reduction in mild hypertension: a systematic review and meta-analysis. Ann Intern Med 2015;162:184–191..
  128. «Visseren, Frank LJ, et al. "2021 ESC Guidelines on cardiovascular disease prevention in clinical practice: Developed by the Task Force for cardiovascular disease prevention in clinical practice with representatives of the European Society of Cardiology,» and 12 medical societies With the special contribution of the European Association of Preventive Cardiology (EAPC)." European heart journal 42.34 (2021): 3227-3337..
  129. Williamson JD, Supiano MA, Applegate WB et al. SPRINT Research Group. Intensive vs standard blood pressure control and cardiovascular disease outcomes in adults aged >_75 years: a randomized clinical trial. JAMA 2016;315:2673–2682..
  130. Beckett N, Peters R, Leonetti G, Duggan J, Fagard R, Thijs L, Narkiewicz K,McCormack T, Banya W, Fletcher A, Bulpitt C, HYVET Study Group. Subgroup and per-protocol analyses from the Hypertension in the Very Elderly Trial. J Hypertens 2014;32:1478–1487..
  131. «Jaeger, Byron C., et al. "Longer-Term All-Cause and Cardiovascular Mortality With Intensive Blood Pressure Control: A Secondary Analysis of a Randomized Clinical Trial." JAMA cardiology 7.11 (2022): 1138-1146.».
  132. Hao G. et al. Effects of ACEI/ARB in hypertensive patients with type 2 diabetes mellitus: a meta-analysis of randomized controlled studies //BMC cardiovascular disorders. – 2014. – Т. 14. – №. 1. – С. 148..
  133. Garrison S. R. et al. Blood pressure targets for hypertension in older adults //Cochrane Database of Systematic Reviews. – 2017. – №. 8..
  134. «Mancia G, Giannattasio C. Diagnostic and therapeutic problems of isolated systolic hypertension. J Hypertens 2015; 33:33–43.».
  135. Prospective Studies Collaboration et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. The Lancet 2002;360(9349):1903–1913..
  136. Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/, American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018;71:e13–e115. DOI: 10.1161/308. HYP.0000000000000065..
  137. «Benetos A, Bulpitt CJ, Petrovic M, et al. An Expert Opinion From the European Society of Hypertension- European Union Geriatric Medicine Society Working Group on the Management of Hypertension in Very Old, Frail Subjects. Hypertension (Dallas, Tex: 1979)».
  138. Dickinson HO, Mason JM, Nicolson DJ et al. Lifestyle interventions to reduce raised blood pressure: a systematic review of randomized controlled trials. J Hypertens 2006;24:215–233..
  139. Lim SS et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010., The Lancet 380.9859 (2012): 2224–2260..
  140. He FJ, Li J, Macgregor GA. Effect of longer-term modest salt reduction on blood pressure. Cochrane Database Syst Rev 2013;4:CD004937..
  141. Graudal NA, Hubeck-Graudal T, Jurgens G. Effects of low-sodium diet vs. highsodium diet on blood pressure, renin, aldosterone, catecholamines, cholesterol, and triglyceride (Cochrane Review). Am J Hypertens 2012;25:1–15..
  142. Taylor RS, Ashton KE, Moxham T, et al. Reduced dietary salt for the prevention of cardiovascular disease: a meta-analysis of randomized controlled trials (Cochrane review). Am J Hypertens 2011;24:843–853..
  143. Aburto NJ, Ziolkovska A, Hooper L, et al. Effect of lower sodium intake on health: systematic review and meta-analyses. BMJ 2013;346:f1326..
  144. B.Neal et al. Effect of Salt Substitution on Cardiovascular Events and Death. N Engl J Med 2021; 385:1067-1077. DOI: 10.1056/NEJMoa2105675.
  145. Xin Xue et al. Effects of alcohol reduction on blood pressure: a meta-analysis of randomized controlled trials. Hypertension 38.5 (2001): 1112–1117..
  146. Gay H. C. et al. Effects of different dietary interventions on blood pressure: systematic review and meta-analysis of randomized controlled trials //Hypertension. – 2016. – Т. 67. – №. 4. – С. 733-739..
  147. «Filippini T, Naska A, Kasdagli MI, Torres D, Lopes C, Carvalho C, et al. Potassium intake and blood pressure: a dose-response meta-analysis of randomized controlled trials. J Am Heart Assoc 2020; 9:e015719.».
  148. «Aburto NJ, Hanson S, Gutierrez H, Hooper L, Elliott P, Cappuccio FP. Effect of increased potassium intake on cardiovascular risk factors and disease: systematic review and meta-analyses. BMJ 2013; 346:f1378.».
  149. «Poorolajal J, Zeraati F, Soltanian AR, Sheikh V, Hooshmand E, Maleki A. Oral potassium supplementation for management of essential hypertension: a meta-analysis of randomized controlled trials. PLoS One 2017; 12:e0174967.».
  150. Neter JE, Stam BE, Kok FJ, et al. Influence of weight reduction on blood pressure: a meta-analysis of randomized controlled trials.Hypertension 2003;42:878–884..
  151. Flegal KM, Kit BK, Orpana H, Graubard BI. Association of all-cause mortality with overweight and obesity using standard body mass index categories: a systematic review and meta-analysis. JAMA 2013;309:71–82..
  152. Berrington de Gonzalez A et al. Body-mass index and mortality among 1.46 million white adults. New England Journal of Medicine 363.23 (2010): 2211–2219..
  153. Leitzmann MF et al. Physical activity recommendations and decreased risk of mortality. Archives of internal medicine 167.22 (2007): 2453–2460..
  154. Rossi A et al. The impact of physical activity on mortality in patients with high blood pressure: a systematic review. Journal of hypertension 30.7 (2012): 1277–1288..
  155. Shinton R, Beevers G. Meta-analysis of relation between cigarette smoking and stroke. Bmj 298.6676 (1989): 789–794..
  156. He Jiang et al. Passive smoking and the risk of coronary heart disease—a meta-analysis of epidemiologic studies. New England Journal of Medicine 340.12 (1999): 920-926..
  157. Linneberg A et al. Effect of smoking on blood pressure and resting heart rate: a mendelian randomization meta-analysis in the CARTA Consortium. Circulation: Cardiovascular Genetics 8.6 (2015): 832–841..
  158. Matsuzaki M, Ogihara T, Umemoto S et al. Combination Therapy of Hypertension to Prevent Cardiovascular Events Trial Group. Prevention of cardiovascular events with calcium channel blocker-based combination therapies in patients with hypertension:, a randomized controlled trial. J Hypertens 2011;29:1649–1659..
  159. MacDonald TM, Williams B, Webb DJ et al. British Hypertension Society Programme of Prevention And Treatment of Hypertension With Algorithm-based Therapy (PATHWAY)., Combination therapy is superior to sequential monotherapy for the initial treatment of hypertension: a double-blind randomized controlled trial. J Am Heart Assoc 2017;6:e006986..
  160. Egan BM, Bandyopadhyay D, Shaftman SR et al. Initial monotherapy and combination therapy and hypertension control the first year. Hypertension 2012;59:1124–1131..
  161. Corrao G, Parodi A, Zambon A, et al. Reduced discontinuation of antihypertensive treatment by two-drug combination as first step. Evidence from daily life practice. J Hypertens 2010;28:1584–1590..
  162. Garjón J. et al. First‐line combination therapy versus first‐line monotherapy for primary hypertension //Cochrane Database of Systematic Reviews. – 2017. – №. 1..
  163. Hermida RC, Crespo JJ, Domínguez-Sardiña M, et al; Hygia Project Investigators. Bedtime hypertension treatment improves cardiovascular risk reduction: the Hygia Chronotherapy Trial. Eur Heart J. 2020 Dec 21;41(48):4565-4576. doi: 10.1093/eurheartj/ehz754..
  164. Poulter NR, Savopoulos C, Anjum A, et al. Randomized Crossover Trial of the Impact of Morning or Evening Dosing of Antihypertensive Agents on 24-Hour Ambulatory Blood Pressure. Hypertension. 2018 Oct;72(4):870-873., doi: 10.1161/HYPERTENSIONAHA.118.11101. PMID: 30354703..
  165. Mackenzie IS, Rogers A, Poulter NR, et al; TIME Study Group. Cardiovascular outcomes in adults with hypertension with evening versus morning dosing of usual antihypertensives in the UK (TIME study): a prospective, randomised, open-label, blinded-endpoint, clinical trial. Lancet. 2022 Oct 22;400(10361):1417-1425. doi: 10.1016/S0140-6736(22)01786-X.
  166. Volpe M, Christian Rump L, Ammentorp B, Laeis P. Efficacy and safety of triple antihypertensive therapy with the olmesartan/amlodipine/hydrochlorothiazide combination. Clin Drug Investig 2012;32:649–664..
  167. Pongpanich P. et al. The benefits of angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers combined with calcium channel blockers on metabolic, renal, and cardiovascular outcomes in hypertensive patients: a meta-analysis, International urology and nephrology. – 2018. – Т. 50. – №. 12. – С. 2261-2278..
  168. Makani H. et al. Efficacy and safety of dual blockade of the renin-angiotensin system: meta-analysis of randomised trials. Bmj 346 (2013): f360..
  169. Fried LF, Emanuele N, Zhang JH, et al. NEPHRON-D Investigators. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med 2013;369:1892–1903..
  170. Yusuf S, Teo KK, Pogue J, et al. ONTARGET Investigators, Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008;358:1547–1559..
  171. «https://www.who.int/europe/activities/promoting-a-more-responsible-use-of-medicines».
  172. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure-lowering on outcome incidence in hypertension: 5. Head-to-head comparisons of various classes of antihypertensive drugs — overview and meta-analyses. J Hypertens 2015;33:1321–1341..
  173. Reboldi G, Angeli F, Cavallini C, Gentile G, Mancia G, Verdecchia P. Comparison between angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on the risk of myocardial infarction, stroke and death: a meta-analysis. J Hypertens 2008;26.
  174. Thomopoulos C, Parati G, Zanchetti A. Effects of blood-pressure-lowering treatment in hypertension: 9. Discontinuations for adverse events attributed to different classes of antihypertensive drugs: meta-analyses of randomized trials., J Hypertens 2016;34:1921–1932.
  175. Kronish IM, Woodward M, Sergie Z, et al. Meta-analysis: impact of drug class on adherence to antihypertensives. Circulation 2011;123:1611–1621..
  176. «Thomopoulos C, Parati G, Zanchetti A. Effects of blood-pressure-lowering treatment on outcome incidence. 12. Effects in individuals with high-normal and normal blood pressure: overview and meta-analyses of randomized trials. J Hypertens 2017;35:2150–2160.».
  177. «Ishani A, Cushman WC, Leatherman SM, et al. Chlorthalidone vs. Hydrochlorothiazide for hypertension–cardiovascular events. N Engl J Med. 2022;387:2401–10».
  178. Olde Engberink, Rik HG, et al. "Effects of thiazide-type and thiazide-like diuretics on cardiovascular events and mortality: systematic review and meta-analysis." Hypertension 65.5 (2015): 1033-1040..
  179. Roush, George C., and Franz H. Messerli. "Chlorthalidone versus hydrochlorothiazide: major cardiovascular events, blood pressure, left ventricular mass, and adverse effects." Journal of Hypertension 39.6 (2021): 1254-1260..
  180. Corrao G, Zambon A, Parodi A, et al. Discontinuation of and changes in drug therapy for hypertension among newly-treated patients: a population-based study in Italy. J Hypertens 2008;26:819–824..
  181. Brown MJ, Williams B, Morant SV, et al. Effect of amiloride, or amiloride plus hydrochlorothiazide, versus hydro- chlorothiazide on glucose tolerance and blood pressure (PATHWAY-3):, a parallel-group, double-blind randomised phase 4 trial. Lancet Diabetes Endocrinol 2016;4:136–147. .
  182. «Cushman WC, Ford CE, Cutler JA, et al., ALLHAT Collaborative Research Group. Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT).,» J Clin Hypertens (Greenwich) 2002; 4:393–404 .
  183. «Palmer BF. Metabolic complications associated with use of diuretics. Semin Nephrol. 2011;31(6):542-52».
  184. Rimoldi SF et al. Efficacy and safety of calcium channel blocker/diuretics combination therapy in hypertensive patients: a meta‐analysis. The Journal of Clinical Hypertension 17.3 (2015):193–199..
  185. Wald DS et al. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. The American journal of medicine 122.3 (2009):290–300..
  186. Kang Seng et al. A systematic review and meta-analysis of the efficacy and safety of a fixed, low-dose perindopril-indapamide combination as first-line treatment of hypertension. Clinical therapeutics 26.2 (2004): 257–270..
  187. «Kizilirmak P, Uresin Y, Yildiz OB. The Efficacy and Safety of Triple vs Dual Combination of Angiotensin II Receptor Blocker and Calcium Channel Blocker and Diuretic: A Systematic Review and Meta‐Analysis.,» The Journal of Clinical Hypertension 15.3 (2013): 193-200..
  188. «Salam A, Atkins ER, Hsu B, Webster R, Patel A, Rodgers A. Efficacy and safety of triple versus dual combination blood pressure-lowering drug therapy: a systematic review and meta-analysis of randomized controlled trials. Journal of hypertension.,» Journal of hypertension. 2019 Aug 1;37(8):1567-73..
  189. «Agarwal R, Sinha AD, Cramer AE, Balmes-Fenwick M, Dickinson JH, Ouyang F, et al. Chlorthalidone for hypertension in advanced chronic kidney disease. N Engl J Med 2021; 385:2507–2519.».
  190. Webb AJS et al. Effects of antihypertensive-drug class on interindividual variation in blood pressure and risk of stroke: a systematic review and meta-analysis. The Lancet 375.9718 (2010): 906–915..
  191. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension: 4. Effects of various classes of antihypertensive drugs — overview and meta-analyses. J Hypertens 2015;33:195–211.
  192. Schmieder R.E. et al. The effect of sacubitril/valsartan compared to olmesartan on cardiovascular remodeling in subjects with essential hypertension: the results of a randomized, double-blind, active-controlled study. Eur Heart J. 2017;38(44):3308–3317.
  193. Williams B. et al. Effects of Sacubitril/Valsartan Versus Olmesartan on Central Hemodynamics in the Elderly With Systolic Hypertension The PARAMETER Study/ Hypertension. 2017;69:411-420.
  194. Izzo J.L., Zappe D.H., Jia Y. et al. Efficacy and Safety of Crystalline Valsartan/Sacubitril (LCZ696) Compared With Placebo and Combinations of Free Valsartan and Sacubitril in Patients With Systolic Hypertension: The RATIO Study/, Cardiovasc Pharmacol. 2017;69:374–381.
  195. Jackson A.M., Jhund S.P., Anand A.S. et al. Sacubitril–valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction/ Euro Heart J. 2021;42:3741-3752.
  196. Geng Q. et al. Effects of LCZ696 (Sacubitril/Valsartan) on Blood Pressure in Patients with Hypertension: A Meta-Analysis of Randomized Controlled Trials/ Cardiology 2020;145:589–598.
  197. Li Q. et al. Effect and safety of LCZ696 in the treatment of hypertension A meta-analysis of 9 RCT studies/ Medicine (Baltimore). 2019; 98(28):e16093.
  198. Zhao Y. et al. The Effects of LCZ696 in Patients With Hypertension Compared With Angiotensin Receptor Blockers: A Meta-Analysis of Randomized Controlled Trials/ J Cardiovasc Pharmacol Ther. 2017; 22(5):447-457.
  199. Wang J. et al. Efficacy and safety of sacubitril/valsartan (LCZ696) add-on to amlodipine in Asian patients with systolic hypertension uncontrolled with amlodipine monotherapy/ J Hypertens. 2017;35(4):877-885.
  200. Solomon S.D. et al. Sacubitril/Valsartan Across the Spectrum of Ejection Fraction in Heart Failure/ Circulation. 2020;141:352–361.
  201. McMurray J.J.V. et al. Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure/ N Engl J Med 2014;371:993-1004.
  202. Bo¨hm M. et al. Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM-HF/ Eur Heart J. 2017;38(15):1132-1143.
  203. Чазова И. Е., Мычка В. Б. Новые возможности в лечении больных с метаболическим синдромом: результаты исследования ALMAZ, Системные гипертензии 2006;2:14–17..
  204. Schlaich MP. Improved hypertension control with the imidazoline agonist moxonidine in a multinational metabolic syndrome population: principal results of the MERSY study. International journal of hypertension 2013 (2013)..
  205. Rayner B. Selective imidazoline agonist moxonidine plus the ACE inhibitor ramipril in hypertensive patients with impaired insulin sensitivity: partners in a successful MARRIAGE? Current medical research and opinion 20.3 (2004): 359–367.. [206] Prichard, B. N. C., et al. "Dose relation of blood pressure reduction with moxonidine: findings from three placebo-and active-controlled randomized studies." Journal of Clinical and Basic Cardiology 6.1 (2003): 49-51..
  206. Prichard, B. N. C., et al. "Dose relation of blood pressure reduction with moxonidine: findings from three placebo-and active-controlled randomized studies." Journal of Clinical and Basic Cardiology 6.1 (2003): 49-51..
  207. Williams B, MacDonald TM, Morant S, et al. British Hypertension Society"s PATHWAY Studies Group. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2):, a randomised, double-blind, crossover trial. Lancet 2015;386:2059–2068..
  208. Chapman, Neil, et al. "Effect of doxazosin gastrointestinal therapeutic system as third-line antihypertensive therapy on blood pressure and lipids in the Anglo-Scandinavian Cardiac Outcomes Trial." Circulation 118.1 (2008): 42-48..
  209. Chernova, Irene, and Namrata Krishnan. "Resistant hypertension updated guidelines." Current Cardiology Reports 21.10 (2019): 1-10..
  210. «Böhm, Michael, Kazuomi Kario, David E. Kandzari, Felix Mahfoud, Michael A. Weber, Roland E. Schmieder, Konstantinos Tsioufis et al. "Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal):,» a multicentre, randomised, sham-controlled trial." The Lancet 395, no. 10234 (2020): 1444-1451..
  211. «Azizi, M., Schmieder, R. E., Mahfoud, F., Weber, M. A., Daemen, J., Davies, J., ... & Renkin, J. (2018). Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, international, single-blind, randomised,,» sham-controlled trial. The Lancet, 391(10137), 2335-2345..
  212. «Azizi, M., Sanghvi, K., Saxena, M., Gosse, P., Reilly, J. P., Levy, T., ... & Ocampo, M. (2021). Ultrasound renal denervation for hypertension resistant to a triple medication pill (RADIANCE-HTN TRIO): a randomised, multicentre, single-blind,,» sham-controlled trial. The Lancet, 397(10293), 2476-2486..
  213. «Kandzari DE, Bohm M, Mahfoud F, Townsend RR, Weber MA, Pocock S, et al., SPYRAL HTN-ON MED Trial Investigators. Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the,» SPYRAL HTN-ON MED proof-of-concept randomised trial. Lancet 2018; 391:2346–2355.
  214. «Kandzari DE. SPYRAL HTN ON Med Extension. AHA. 2022.».
  215. «Biffi A, Dell’Oro R, Quarti-Trevano F, et al. Effects of renal denervation on sympathetic nerve traffic and correlates in drug-resistant and uncontrolled hypertension: a systematic review and meta-analysis. Hypertension 2023; 80:659–667.».
  216. DiBona GF. Physiology in perspective: the wisdom of the body. Neural control . of the kidney. Am J Physiol Regul Integr Comp Physiol 2005;289:R633–R641..
  217. Narkiewicz K, Ratcliffe LE, Hart EC, et al. Unilateral carotid body resection in resistant hypertension: a safety and feasibility trial. JACC Basic Transl Sci 2016;1:313–324..
  218. Mahfoud F, Bohm M, Azizi M et al. Proceedings from the European Clinical Consensus Conference for Renal Denervation: considerations on future clinical trial design. Eur Heart J 2015;36:2219–2227..
  219. «Kirtane AJ, Sharp ASP, Mahfoud F, et al., RADIANCE Investigators and Collaborators. Patient-level pooled analysis of ultrasound renal denervation in the sham-controlled RADIANCE II, RADIANCE-HTN SOLO, and RADIANCE-HTN TRIO trials. JAMA Cardiol 2023; 8:464».
  220. «Townsend RR, Walton A, Hettrick DA, et al. Review and meta-analysis of renal artery damage following percutaneous renal denervation with radiofrequency renal artery ablation. EuroIntervention 2020; 16:89–96.».
  221. «Lauder L, Azizi M, Kirtane AJ,et al. Device-based therapies for arterial hypertension. Nat Rev Cardiol 2020; 17:614–628.».
  222. Sarafidis, P. A., Lazaridis, A. A., Ruiz-Hurtado, G. & Ruilope, L. M. Blood pressure reduction in diabetes: lessons from ACCORD, SPRINT and EMPA-REG OUTCOME. Nat. Rev. Endocrinol. http://dx.doi.org/10.1038/nrendo.2016.209 (2017)..
  223. Patel A, ADVANCE Collaborative Group, MacMahon S, et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial..
  224. Thomopoulos C, Parati G, Zanchetti A. Effects of blood-pressure-lowering treatment on outcome incidence in hypertension: 10 — Should blood pressure management differ in hypertensive patients with and without diabetes mellitus?, Overview and meta-analyses of randomized trials. J Hypertens 2017;35:922–944. .
  225. Kario K. et al. Comparative Effects of an Angiotensin II Receptor Blocker (ARB)/Diuretic vs. ARB/Calcium-Channel Blocker Combination on Uncontrolled Nocturnal Hypertension Evaluated by Information and Communication Technology-Based, Nocturnal Home Blood Pressure Monitoring―The NOCTURNE Study― //Circulation Journal. – 2017. – Т. 81. – №. 7. – С. 948-957..
  226. Tsai WC, Wu HY, Peng YS, et al. Association of intensive blood pressure control and kidney disease progression in nondiabetic patients with chronic kidney disease: a systematic review and meta-analysis. JAMA Intern Med 2017;177:792–799..
  227. SPRINT Research Group. A randomized trial of intensive versus standard blood pressure control. New England Journal of Medicine 2015;373(22):2103–2116..
  228. Cheung AK, Rahman M, Reboussin DM, et al. Effects of intensive BP control in CKD. J Am Soc Nephrol. 2017;28:2812-2823..
  229. Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group. KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. Kidney Int.2021;99(3S):S1–S87..
  230. Papademetriou V, Zaheer M, Doumas M, et al. Cardiovascular Outcomes in Action to Control Cardiovascular Risk in Diabetes: Impact of Blood Pressure Level and Presence of Kidney Disease. American Journal of Nephrology 2016;43(4):271-280.
  231. Blood Pressure Lowering Treatment Trialists Collaboration, Ninomiya T, Perkovic V, et al. Blood pressure lowering and major cardiovascular events in people with and without chronic kidney disease: meta-analysis of randomised controlled trials. BMJ. 2013;3.
  232. Beddhu S, Chertow GM, Greene T, et al. Effects of intensive systolic blood pressure lowering on cardiovascular events and mortality in patients with type 2 diabetes mellitus on standard glycemic control and in those without diabetes mellitus:, reconciling results from ACCORD and SPRINT. J Am Heart Assoc. 2018;7:e009326..
  233. Tsujimoto T, Kajio H. Benefits of Intensive blood pressure treatment in patients with type 2 diabetes mellitus receiving standard but not intensive glycemic control. Hypertension. 2018;72:323-330..
  234. Aggarwal R, Petrie, Bala W, et al. Mortality outcomes with intensive blood pressure targets in chronic kidney disease patients. Hypertension. 2019;73:1275-1282..
  235. Jafar TH, Stark PC, Schmid CH, et al. AIPRD Study Group. Progression of chronic kid- ney disease: the role of blood pressure control, proteinuria, and angiotensin- converting enzyme inhibition: a patient-level meta-analysis. Ann Intern Med 2003;139:244–25.
  236. «Deng, Xiaojuan, et al. "ACEI and ARB Lower the Incidence of End‐Stage Renal Disease among Patients with Diabetic Nephropathy: A Meta‐analysis." Computational and Mathematical Methods in Medicine 2022.1 (2022): 6962654.».
  237. «Zhang, Yaru, et al. "ACE inhibitor benefit to kidney and cardiovascular outcomes for patients with non-dialysis chronic kidney disease stages 3–5: a network meta-analysis of randomised clinical trials." Drugs 80 (2020): 797-811.».
  238. «Xie, Xinfang, et al. "Renin-angiotensin system inhibitors and kidney and cardiovascular outcomes in patients with CKD: a Bayesian network meta-analysis of randomized clinical trials." American Journal of Kidney Diseases 67.5 (2016): 728-741.».
  239. «Huang, Rongzhong, et al. "Comparative efficacy and safety of antihypertensive agents for adult diabetic patients with microalbuminuric kidney disease: a network meta-analysis." PloS one 12.1 (2017): e0168582.».
  240. «Cho, Miseung, et al. "Clinical outcomes of renin angiotensin system inhibitor-based dual antihypertensive regimens in chronic kidney disease: a network meta-analysis." Scientific Reports 13.1 (2023): 5727.».
  241. «Agarwal R, Sinha AD, Tu W. Chlorthalidone for resistant hypertension in advanced chronic kidney disease. Circulation 2022; 146:718–720.».
  242. Heerspink HJL, Stefánsson BV, Correa-Rotter R, Chertow GM, Greene T, et al; DAPA-CKD Trial Committees and Investigators. Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2020 Oct 8;383(15):1436-1446. doi: 10.1056/NEJMoa2024816..
  243. EMPA-KIDNEY Collaborative Group, Herrington WG, Staplin N, Wanner C, Green JB, Hauske SJ, et al. Empagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2022 Nov 4. doi: 10.1056/NEJMoa2204233..
  244. «Agarwal R, Filippatos G, Pitt B, et al. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur Heart J 2022; 43:474–484.».
  245. «Bakris GL, Agarwal R, Anker SD, et al. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. N Engl J Med 2020; 383:2219–2229.».
  246. «Brunstrom M, Carlberg B. Association of blood pressure lowering with mortality and cardiovascular disease across blood pressure levels: a systematic review and meta-analysis. JAMA Intern Med 2018; 178:28–36.».
  247. Xie X, Atkins E, Lv J et al. Effects of intensive blood pressure lowering on cardio- vascular and renal outcomes: updated systematic review and meta-analysis. Lancet 2016;387:435–443..
  248. Vidal-Petiot E. et al. Cardiovascular event rates and mortality according to achieved systolic and diastolic blood pressure in patients with stable coronary artery disease: an international cohort study. The Lancet 2016; 388(10056):2142–2152..
  249. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009;338:b1665..
  250. «Manolis AJ, Boden WE, Collins P, et al. State of the art approach to managing angina and ischemia: tailoring treatment to the evidence. Eur J Intern Med 2021; 92:40–47.».
  251. «Bangalore S, Makani H, Radford M, et al. Clinical outcomes with b-blockers for myocardial infarction: a meta-analysis of randomized trials. Am J Med 2014; 127:939–953.».
  252. «Bangalore, Sripal, et al. "Renin angiotensin system inhibitors for patients with stable coronary artery disease without heart failure: systematic review and meta-analysis of randomized trials." bmj 356 (2017).».
  253. «Fagard RH, Celis H, Thijs L, Wouters S. Regression of left ventricular mass by antihypertensive treatment: a meta-analysis of randomized comparative studies. Hypertension 2009;54:1084–1091.».
  254. «Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure-lowering treatment. 6. Prevention of heart failure and new-onset heart failure--meta-analyses of randomized trials. J Hypertens 2016;34:373–384.».
  255. «Dahlöf, Björn, et al. "Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol." The Lancet 359.9311 (2002): 995-1003.».
  256. McDonagh, Theresa A., et al. "2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology, (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC." European heart journal 42.36 (2021): 3599-3726..
  257. Writing Committee Members; ACC/AHA Joint Committee Members. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure. J Card Fail. 2022.
  258. Zhang, Hongzhou, et al. "Efficacy and safety of sacubitril‐valsartan in heart failure: a meta‐analysis of randomized controlled trials." ESC heart failure 7.6 (2020): 3841-3850..
  259. Cleophas, T. J., and A. H. Zwinderman. "Beta-blockers and heart failure: meta-analysis of mortality trials." International journal of clinical pharmacology and therapeutics 39.9 (2001): 383-388..
  260. Berbenetz, Nicolas M., and Marko Mrkobrada. "Mineralocorticoid receptor antagonists for heart failure: systematic review and meta-analysis." BMC cardiovascular disorders 16.1 (2016): 1-10..
  261. Chatterjee S, Biondi-Zoccai G, Abbate A, et al. Benefits of β blockers in patients with heart failure and reduced ejection fraction: network meta-analysis. BMJ. 2013;346(jan16 1):f55. doi:10.1136/bmj.f55.
  262. Zannad, F., McMurray, J. J., Krum, H., et al & EMPHASIS-HF Study Group (2011). Eplerenone in patients with systolic heart failure and mild symptoms. The New England journal of medicine, 364(1), 11–21. https://doi.org/10.1056/NEJMoa1009492.
  263. «Burnett, Heather, et al. "Thirty years of evidence on the efficacy of drug treatments for chronic heart failure with reduced ejection fraction: a network meta-analysis." Circulation: Heart Failure 10.1 (2017): e003529.».
  264. Shah RV, Akshay SD, Givertz MM. The effect of renin-angiotensin system inhibitors on mortality and heart failure hospitalization in patients with heart failure and preserved ejection fraction: a systematic review and meta-analysis., Journal of cardiac failure 16.3 (2010): 260–267..
  265. Packer M., O’Connor C.M., Ghali J.K. et al. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group. N Engl J Med. 1996; 335 (15):1107–1114.;.
  266. Packer, M., Carson, P., Elkayam, U., Konstam, M. A., Moe, G., O’Connor, C., DeMets, D. L. (2013). Effect of Amlodipine on the Survival of Patients With Severe Chronic Heart Failure Due to a Nonischemic Cardiomyopathy. JACC: Heart Failure, 1(4), 308–314..
  267. Goldstein R.E., Boccuzzi S.J., Cruess D., Nattel S. Diltiazem increases late-onset congestive heart failure in postinfarction patients with early reduction in ejection fraction. The Adverse Experience Committee; and the Multicenter Diltiazem, Postinfarction Research Group. Circulation 1991;83:52–60; .
  268. Physicians Desk Reference. 47th ed. Montvale. NJ: Medical Economics Company, 1993: 2250.
  269. «Инструкция по медицинскому применению препарата Верапамил https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=d5c7f87f-8a1d-49cf-a3df-c80df3ab5159».
  270. «Hansen JF. Treatment with verapamil after an acute myocardial infarction. Review of the Danish studies on verapamil in myocardial infarction (DAVIT I and II). Drugs. 1991;42 Suppl 2:43-53. doi: 10.2165/00003495-199100422-00008. PMID: 1718701.».
  271. Cohn JN, Pfeffer MA, Rouleau J, Sharpe N, Swedberg K, Straub M, Wiltse C, Wright TJ, MOXCON Investigators. Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure (MOXCON)., Eur J Heart Fail 2003;5:659–667..
  272. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone. ALLHAT Collaborative Research Group. JAMA 2000;283: 1967–1975.;.
  273. Dorszewski A, Go¨hmann E, Dorsz´ewski B, Werner GS, Kreuzer H, Figulla HR. Vasodilation by urapidil in the treatment of chronic congestive heart failure in addition to angiotensin-converting enzyme inhibitors is not beneficial:, results of a placebo-controlled, double-blind study. J Card Fail 1997;3:91–96.;.
  274. Bayliss J, Norell MS, Canepa-Anson R, Reid C, Poole-Wilson P, Sutton G. Clinical importance of the renin-angiotensin system in chronic heart failure: double blind comparison of captopril and prazosin. Br Med J (Clin Res Ed) 1985;290:1861–1865.
  275. Faris R, Flather M, Purcell H, Henein M, Poole-Wilson P, Coats A. Current evidence supporting the role of diuretics in heart failure: a meta analysis of randomized controlled trials. Int J Cardiol 2002;82:149-158..
  276. Faris R.F., Flather M., Purcell H., Poole-Wilson P.A., Coats A.J. Diuretics for heart failure.Cochrane Database Syst Rev 2012;2:CD003838..
  277. Mc Causland FR, Lefkowitz MP, Claggett B, Anavekar NS, Senni M, et al. Angiotensin-Neprilysin Inhibition and Renal Outcomes in Heart Failure With Preserved Ejection Fraction. Circulation. 2020 Sep 29;142(13):1236-1245. doi: 10.1161/CIRCULATIONAHA.120.0.
  278. Cleland JGF, Bunting KV, Flather MD, Altman DG, Holmes J, Coats AJS, et al. Beta-blockers in Heart Failure Collaborative Group. Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis, of double-blind randomized trials. Eur Heart J 2018;39:26-35.
  279. Lund LH, Claggett B, Liu J, Lam CS, Jhund PS, Rosano GM, Swedberg K, Yusuf S, Granger CB, Pfeffer MA, McMurray JJV, Solomon SD. Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across, the entire ejection fraction spectrum. Eur J Heart Fail. 2018 Aug; 20:1230-1239. .
  280. Solomon SD, Claggett B, Lewis EF, Desai A, Anand I, Sweitzer NK, O"Meara E, Shah SJ, McKinlay S, Fleg JL, Sopko G, Pitt B, Pfeffer MA; TOPCAT Investigators. Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart, failure with preserved ejection fraction. Eur Heart J. 2016; 37: 455-62..
  281. Solomon SD, McMurray JJV, Claggett B, de Boer RA, DeMets D, et al; DELIVER Trial Committees and Investigators. Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. N Engl J Med. 2022 Sep 22;387(12):1089-1098. doi: 10.1056/NEJ.
  282. Anker S, Butler J, Filippatos G, et al. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. N Engl J Med. 2021;10.1056/NEJMoa2107038.
  283. Lin, Yaowang, et al. "Effect of pharmacological treatment on outcomes of heart failure with preserved ejection fraction: an updated systematic review and network meta-analysis of randomized controlled trials." Cardiovascular Diabetology 21.1 (2022): 1-10..
  284. Cleland JGF, Tendera M, Adamus J, Freemantle N, Polonski L, Taylor J. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J 2006;27:2338–2345..
  285. Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ V, Michelson EL, Olofsson B, Ostergren J. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet.
  286. Myhre PL, Vaduganathan M, Claggett BL et al. Association of Natriuretic Peptides With Cardiovascular Prognosis in Heart Failure With Preserved Ejection Fraction: Secondary Analysis of the TOPCAT Randomized Clinical Trial. JAMA Cardiol ., 2018 Oct 1;3(10):1000-1005. doi: 10.1001/jamacardio.2018.2568..
  287. Martin N, Manoharan K, Thomas J, Davies C, Lumbers RT. Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction. Cochrane Database Syst Rev 2018 Jun 28;6:CD012721.
  288. Hernandez AF, Hammill BG, O"Connor CM, Schulman KA, Curtis LH, Fonarow GC. Clinical effectiveness of beta-blockers in heart failure: findings from the OPTIMIZE-HF (Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with, Heart Failure) Registry. J Am Coll Cardiol. 2009 Jan 13;53(2):184-92.
  289. Azizova A.G., Ovchinnikov A.G., Blankova Z.N., Ageev F.T. In patients with elevated LV filling pressure loop diuretics improve severity of heart failure and diastolic dysfunction, but torasemide does it somewhat better than furosemide., Eur J Heart Fail 2011;10 (Suppl 2):S186..
  290. Adamson PB, Abraham WT, Bourge RC, Costanzo MR, Hasan A, Yadav C, et al. Wireless pulmonary artery pressure monitoring guides management to reduce decompensation in heart failure with preserved ejection fraction. Circ Heart Fail. 2014 Nov;7(6):935-44..
  291. Cardoso, Rhanderson, et al. "SGLT2 inhibitors decrease cardiovascular death and heart failure hospitalizations in patients with heart failure: A systematic review and meta-analysis." EClinicalMedicine 36 (2021): 100933..
  292. Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B, et al.; TOPCAT Investigators. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med. 2014;370(15):1383-92. doi: 10.1056/NEJMoa1313731.
  293. Soliman EZ et al. Effect of intensive blood pressure lowering on left ventricular hypertrophy in patients with hypertension: SPRINT (Systolic Blood Pressure Intervention Trial). Circulation 2017:136(5):440–450..
  294. Klingbeil AU et al. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. The American journal of medicine 115.1 (2003):41–46..
  295. Dahlöf B, Kjell P, Hansson L. Reversal of left ventricular hypertrophy in hypertensive patients: a metaanalysis of 109 treatment studies. 1992. P. 95–110..
  296. КР. Фибрилляция и трепетание предсердий у взрослых. 2020. https://cr.minzdrav.gov.ru/recomend/382_1.
  297. Hart RG et al. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Annals of internal medicine 131 (1999):492–501; 536, 556..
  298. Arima H, Chalmers J, Woodward M, et al. PROGRESS Collaborative Group. Lower target blood pressures are safe and effective for the prevention of recurrent stroke: the PROGRESS trial. J Hypertens 2006;24:1201–1208..
  299. Rodriguez-Luna D, Pineiro S, Rubiera M, et al. Impact of blood pressure changes and courseon hematoma growth in acute intracerebral hemorrhage. Eur J Neurol.2013;20:1277–1283..
  300. Sakamoto Y, Koga M, Yamagami H et al. Systolic blood pressure afterintravenous antihypertensive treatment and clinical outcomes in hyperacute intracerebral hemorrhage: the stroke acute management with urgent risk-factorassessment and improvement, intracerebral hemorrhage study. Stroke.2013;44:1846–1851..
  301. Anderson CS, Heeley E, Huang Y, et al. INTERACT2Investigators. Rapid blood-pressure lowering in patients with acute intracerebral hemorrhage. N Engl J Med 2013;368:2355–2365..
  302. Qureshi AI, Palesch YY, Barsan WG, et al. Intensive blood-pressure lowering in patients with acute cerebral hemorrhage. . N Engl J Med 2016;375:1033–1043..
  303. Tsivgoulis G, Katsanos AH, Butcher KS et al. Intensive blood pressure reduction in acute intracerebral hemorrhage: a meta-analysis. Neurology 2014;83:1523–1529..
  304. «Moullaali TJ, Wang X, Martin RH, et al. Blood pressure control and clinical outcomes in acute intracerebral haemorrhage: a preplanned pooled analysis of individual participant data. Lancet Neurol. 2019;18(9):857-864.».
  305. Steiner et al. European Stroke Organisation (ESO) guidelines for the management of spontaneous intracerebral hemorrhage. International Journal of Stroke, Vol. 9, October 2014, p. 840–855..
  306. Hemphill et al. Guidelines for the Management of Spontaneous Intracerebral Hemorrhage. A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke. 2015;46:2032–2060. doi: 10.1161/STR.0000000000000069]..
  307. Powers WJ et al. 2018 Guidelines for the Early Management of Patients With Acute Ischemic Stroke. A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke 2018; 49 (3): e46–e138..
  308. Lee M, Ovbiagele B, Hong KS, et al. Effectof blood pressure lowering in early ischemic stroke: meta-analysis. Stroke.2015;46:1883–1889..
  309. Zhao R, Liu FD, Wang S et al. Blood pressure reduction in the acute phase of an ischemic stroke does not improve short- or long-term dependency or mortality: a meta-analysis of current literature. Medicine(Baltimore). 2015;94:e896..
  310. Ahmed N, Wahlgren N, Brainin M, et al. Relationship of blood pressure, antihypertensive therapy, and outcome inischemic stroke treated with intravenous thrombolysis: retrospective analysis from Safe Implementation of Thrombolysis in Stroke-International, StrokeThrombolysis Register (SITS-ISTR). Stroke 2009;40:2442–2449..
  311. WuW, HuoX, ZhaoX, et al. Relationship between blood pressure and outcomes in acute ischemic stroke patients administered lytic medication in the TIMS-China Study. PLoS One 2016;11:e0144260..
  312. White CL, Szychowski JM, Pergola PE et al. Secondary Prevention of Small Subcortical Strokes Study Investigators. Can blood pressure be lowered safely in older adults with lacunar stroke? The Secondary Prevention of Small Subcortical Strokes study, experience. J Am Geriatr Soc 2015;63:722–729..
  313. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. The Lancet 358.9287 (2001):1033–1041..
  314. «Lu, Z., et al. "Combination therapy of renin–angiotensin system inhibitors plus calcium channel blockers versus other two-drug combinations for hypertension: a systematic review and meta-analysis." Journal of Human Hypertension 31.1 (2017): 1-13.».
  315. Chi C, Tai C, Bai B, et al. Angiotensin System Blockade Combined With Calcium Channel Blockers Is Superior to Other Combinations in Cardiovascular Protection With Similar Blood Pressure Reduction: A Meta-Analysis in 20,451 Hypertensive Patients., J Clin Hypertens (Greenwich). 2016 Aug;18(8):801-8. doi: 10.1111/jch.12771..
  316. Wang Ji-Guang et al. Carotid intima-media thickness and antihypertensive treatment: a meta-analysis of randomized controlled trials. Stroke 37.7 (2006): 1933–1940..
  317. Lane D. A., Lip G. Y. H. Treatment of hypertension in peripheral arterial disease //Cochrane database of systematic reviews. – 2013. – №. 12..
  318. Zanchetti A, Hennig M, Hollweck R et al. Baseline values but not treatment-induced changes incarotid intima-media thickness predict incident cardiovascular events in treatedhypertensive patients: findings in the European Lacidipine Study on Atherosclerosi.
  319. Zanchetti A, Crepaldi G, Bond MG, et al. PHYLLIS Investigators. Different effects of antihypertensive regimens based on fosinopril or hydrochlorothiazide with or without lipid lowering by pravastatin on progression of asymptomatic carotid atherosclerosis:, principal results of PHYLLIS–a randomized double-blind trial. Stroke 2004;35:2807–2812..
  320. Myou S, Fujimura M, Kamio Y, et al.Effect of losartan, a type 1 angiotensin II receptor antagonist, on bronchial hyperresponsiveness to methacholine in patients with bronchial asthma. Am J Respir Crit Care Med 2000;162:40-4..
  321. Chiu KY, Li JG, Lin Y. Calcium channel blockers for lung function improvement in asthma: A systematic review and meta-analysis. Ann Allergy Asthma Immunol 2017;119(6):518-523.e3..
  322. Mortensen EM, Copeland LA, Pugh MJV, et al. Impact of statins and ACE inhibitors on mortality after COPD exacerbations. Respir Res. 2009;10:45.
  323. Tanaka H, Teramoto S, Oashi K, et al. Effects of candesartan on cough and bronchial hyperresponsiveness in mildly to moderately hypertensive patients with symptomatic asthma. Circulation. 2001;104(3):281–285..
  324. «Huang KY, Tseng PT, Wu YC, et al. Do beta-adrenergic blocking agents increase asthma exacerbation? A network meta-analysis of randomized controlled trials. Scientific reports. 2021 Jan 11;11(1):452.».
  325. «Global initiative for asthma. Global strategy for asthma management and prevention (http://www.ginasthma.org).».
  326. «Bennett M, Chang CL, Tatley M, Savage R, Hancox RJ. The safety of cardioselective β1-blockers in asthma: literature review and search of global pharmacovigilance safety reports. ERJ Open Research. 2021 Jan 1;7(1).».
  327. «Song WJ, Niimi A. Angiotensin-Converting Enzyme Inhibitors, Asthma, and Cough: Relighting the Torch. J Allergy Clin Immunol Pract. 2021 Sep;9(9):3440-3441. doi: 10.1016/j.jaip.2021.07.002.».
  328. «Finks SW, Rumbak MJ, Self TH. Treating Hypertension in Chronic Obstructive Pulmonary Disease. N Engl J Med 2020; 382:353–363».
  329. «ang YL, Xiang ZJ, Yang JH, Wang WJ, Xu ZC, Xiang RL. Association of β-blocker use with survival and pulmonary function in patients with chronic obstructive pulmonary and cardiovascular disease: a systematic review and meta-analysis.,» Eur Heart J 2020; 41:4415–4422..
  330. «Dos Santos NC, Camelier AA, Menezes AK, et al. EFFECTS OF THE USE OF BETA-BLOCKERS ON CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) ASSOCIATED WITH CARDIOVASCULAR COMORBITIES: SYSTEMATIC REVIEW AND META-ANALYSIS. Tuberc Respir Dis (Seoul). 2024 Apr 4.,» doi: 10.4046/trd.2024.0013..
  331. «Fava, C., Dorigoni, S., Dalle Vedove, F., Danese, E., Montagnana, M., Guidi, G.C., Narkiewicz, K. and Minuz, P., 2014. Effect of CPAP on blood pressure in patients with OSA/hypopnea: a systematic review and meta-analysis. Chest, 145(4), pp.762-771.».
  332. «Labarca, G., Schmidt, A., Dreyse, J., Jorquera, J., Enos, D., Torres, G. and Barbe, F., 2021. Efficacy of continuous positive airway pressure (CPAP) in patients with obstructive sleep apnea (OSA) and resistant hypertension (RH):,» systematic review and meta-analysis. Sleep Medicine Reviews, 58, p.101446..
  333. Сукмарова З. Н., Литвин А. Ю., Чазова И. Е., Рогоза А. Н. Эффективность комплексной медикаментозной и CPAP-терапии у пациентов с артериальной гипертонией 2–3-й степени и тяжелой степенью синдрома обструктивного апноэ во время сна., ФГУ РКНПК Минздравсоцразвития РФ, Москва. Системные гипертензии, 2011:8(1), 40.
  334. Kristensen SD, Knuuti J, Saraste A, et al. 2014 ESC/ESAGuidelines on non-cardiac surgery: cardiovascular assessment and management:The Joint Task Force on non-cardiac surgery: cardiovascular assessment andmanagement of the European Society of Cardiology, (ESC) and the EuropeanSociety of Anaesthesiology (ESA). Eur Heart J 2014;35:2383–2431..
  335. Futier E, Lefrant JY, Guinot PG et al. Effect of individualized vs standardblood pressure management strategies on postoperative organ dysfunctionamong high-risk patients undergoing major surgery: a randomized clinical trial. JAMA 2017;318:1346–1357..
  336. London MJ, Hur K, Schwartz GG, Henderson WG. Association of perioperative beta-blockade with mortality and cardiovascular morbidity following major non-cardiac surgery. JAMA 2013;309:1704–1713..
  337. Andersson C, Merie C, Jorgensen M, et al. Association of beta-blocker therapy with risks of adverse cardiovascular events and deaths in patients with ischemic heart disease undergoing noncardiac surgery: a Danish nationwidecohort study., JAMA Intern Med 2014;174:336–344. .
  338. Lederballe Pedersen O, Mikkelsen E, Lanng Nielsen J, Christensen NJ. Abrupt withdrawal of beta-blocking agents in patients with arterial hypertension. Effect on blood pressure, heart rate and plasma catecholamines and prolactin. Eur J Clin Pharmacol. 1979.
  339. Gupta P, Patel P, Strauch B et al. Biochemical screening for nonadherence is associated with blood pressure reduction and improvement in adherence. Hypertension 2017;70:1042–1048..
  340. «Achelrod D, Wenzel U, Frey S. Systematic review and meta-analysis of the prevalence of resistant hypertension in treated hypertensive populations. Am J Hypertens 2015; 28:355–361.».
  341. «Kario K, Hoshide S, Narita K, et al Cardiovascular prognosis in drug-resistant hypertension stratified by 24-hour ambulatory blood pressure: the JAMP Study. Hypertension 2021; 78:1781–1790.».
  342. «Cuspidi C, Macca G, Sampieri L, et al. High prevalence of cardiac and extracardiac target organ damage in refractory hypertension. J Hypertens 2001; 19:2063–2070.».
  343. Pimenta E, Gaddam KK, Oparil S, et al. Effects of dietary sodium reduction on blood pressure in subjects with resistanthypertension: results from a randomized trial. Hypertension 2009;54:475–481..
  344. Liu L, Xu B, Ju Y. Addition of spironolactone in patients with resistant hypertension: a meta-analysis of randomized controlled trials. Clin Exp Hypertens.2017;39:257–263..
  345. Wang C, Xiong B, Huang J. Efficacy and safety of spironolactone in patients with resistant hypertension: a meta-analysis of randomised controlled trials.Heart Lung Circ 2016;25:1021–1030..
  346. «Chen C, Zhu XY, Li D, et al Clinical efficacy and safety of spironolactone in patients with resistant hypertension: a systematic review and meta-analysis. Medicine (Baltimore) 2020; 99:e21694.».
  347. «Krieger EM, Drager LF, Giorgi DMA, et al., ReHOT Investigators. Spironolactone versus clonidine as a fourth-drug therapy for resistant hypertension: the ReHOT Randomized Study (Resistant Hypertension Optimal Treatment). Hypertension 2018;71:681 – 690».
  348. «Williams B, MacDonald TM, Morant SV, et al., British Hypertension Society programme of Prevention And Treatment of Hypertension With Algorithm based Therapy (PATHWAY) Study Group. Endocrine and haemodynamic changes in resistant hypertension, and,» blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms substudies. Lancet Diabetes Endocrinol 2018; 6:464–475..
  349. «Desai R, Park H, Brown JD, et al Comparative safety and effectiveness of aldosterone antagonists versus beta-blockers as fourth agents in patients with apparent resistant hypertension. Hypertension 2022; 79:2305–2315.».
  350. «Sinnott, Sarah-Jo, et al. "Comparative effectiveness of fourth-line anti-hypertensive agents in resistant hypertension: A systematic review and meta-analysis." European journal of preventive cardiology 24.3 (2017): 228-238.».
  351. «Bolignano D, Palmer SC, Navaneethan SD, Strippoli GF. Aldosterone antagonists for preventing the progression of chronic kidney disease. Cochrane Database Syst Rev 2014; 4:CD007004.».
  352. «Loutradis C, Sarafidis P. Hypertension in patients with advanced chronic kidney disease. In: Mancia G, Grassi G, Tsioufis K, Dominiczak A, Rosei EA, editors. Manual of hypertension of the European Society of Hypertension. Boca Raton: CRC Press; 2019.».
  353. «Tamargo J, Segura J, Ruilope LM. Diuretics in the treatment of hypertension. Part 2: loop diuretics and potassium-sparing agents. Expert Opin Pharmacother 2014; 15:605–621.».
  354. «Azizi M. The Radiance II Trial. JAMA Cardiol 2022; [in press].».
  355. «Kandzari DE, Bohm M, Mahfoud F, Townsend RR, Weber MA, Pocock S, et al., SPYRAL HTN-ON MED Trial Investigators. Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the,» SPYRAL HTN-ON MED proof-of-concept randomised trial. Lancet 2018; 391:2346–2355.
  356. «Hu X, Fan J, Chen S, et al The role of continuous positive airway pressure in blood pressure control for patients with obstructive sleep apnea and hypertension: a meta-analysis of randomized controlled trials. J Clin Hypertens (Greenwich) 2015; 17:215–222».
  357. «Martinez-Garcia MA, Pengo MF. Clinical phenotype of resistant hypertension responders to continuous positive airway pressure treatment: results from the HIPARCO Randomized Clinical Trial. Hypertension 2021; 78:559–561.».
  358. «Shi Q, Wang Y, Hao Q, et al. Pharmacotherapy for adults with overweight and obesity: a systematic review and network meta-analysis of randomised controlled trials. Lancet 2022; 399:259–269.».
  359. «Maringwa J, Sardu ML, Hang Y, et al. Characterizing effects of antidiabetic drugs on heart rate, systolic and diastolic blood pressure. Clin Pharmacol Ther 2021; 109:1583–1592.».
  360. «Giugliano D, Scappaticcio L, Longo M, et al. GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes: an updated meta-analysis of eight CVOTs. Cardiovasc Diabetol 2021; 20:189.».
  361. «Schiavon CA, Ikeoka D, Santucci EV, et al. Effects of bariatric surgery versus medical therapy on the 24-hour ambulatory blood pressure and the prevalence of resistant hypertension. Hypertension 2019; 73:571–577.».
  362. «Georgianos PI, Agarwal R. Ambulatory blood pressure reduction with SGLT-2 inhibitors: dose-response meta-analysis and comparative evaluation with low-dose hydrochlorothiazide. Diabetes Care 2019; 42:693–700.».
  363. Ruilope L.M. et al. Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin:a randomised, double-blind, placebo-controlled, active comparator study/ Lancet 2010; 375: 1255–66.
  364. Huang Y, Huang W, Mai W, et al. White-coat hypertension is a risk factor for cardiovascular diseases and total mortality. J Hypertens 2017;35:677–688..
  365. Briasoulis A, Androulakis E, Palla M, et al. White-coat hypertension and cardiovascular events: a meta-analysis. J Hypertens 2016;34:593–599..
  366. Cuspidi C, Rescaldani M, Tadic M, et al. White-coat hypertension, as defined by ambulatory blood pressure monitoring, and subclinical cardiac organ damage: a meta-analysis. J Hypertens 2015;33:24–32.
  367. Mancia G, Bombelli M, Facchetti R, et al. Increased long-term risk of new-onset diabetes mellitus in white-coat and masked hypertension. J Hypertens 2009;27:1672–1678..
  368. Tientcheu D, Ayers C, Das SR, et al. Target organ complications and cardiovascular events associated with masked hypertension and white-coat hypertension: analysis from the Dallas Heart Study. J Am Coll Cardiol 2015;66:2159–2169..
  369. «Stergiou GS, Asayama K, Thijs L, et al., International Database on HOme blood pressure in relation to Cardiovascular Outcome (IDHOCO) Investigators. Prognosis of white-coat and masked hypertension: International Database of HOme blood pressure in relation,» to Cardiovascular Outcome. Hypertension 2014; 63:675–682..
  370. Thakkar H. V., Pope A., & Anpalahan, M. Masked Hypertension: A Systematic Review. Heart, Lung and Circulation. 2019..
  371. «Palla M, Saber H, Konda S, Briasoulis A. Masked hypertension and cardiovascular outcomes: an updated systematic review and meta-analysis. Integr Blood Press Control 2018; 11:11–24.».
  372. «Zhang DY, Guo QH, An DW, et al. A comparative meta-analysis of prospective observational studies on masked hypertension and masked uncontrolled hypertension defined by ambulatory and home blood pressure. J Hypertens 2019; 37:1775–1785.».
  373. Egan BM, Li J, Hutchison FN, Ferdinand KC. Hypertension in the United States, 1999 to 2012: progress toward Healthy People 2020 goals. Circulation. 2014;130(19):1692–1699..
  374. Liu X, Rodriguez CJ, Wang K. Prevalence and trends of isolated systolic hypertension among untreated adults in the United States. J Am Soc Hypertens. 2015;9(3):197–205..
  375. Bavishi C, Goel S, Messerli FH. Isolated Systolic Hypertension: An Update After SPRINT Am J Med. 2016;129(12):1251–1258..
  376. Ekundayo OJ, Allman RM, Sanders PW, et al. Isolated systolic hypertension and incident heart failure in older adults: a propensity-matched study. Hypertension. 2009;53(3):458–465..
  377. Li Y, Wei FF, Thijs L et al. Ambulatory hypertension subtypes and 24-hour systolic and diastolic blood pressure as distinct outcome predictors in 8341 untreated people recruited from 12 populations. Circulation. 2014;130(6):466–474..
  378. «SHEP Cooperative Research Group. Prevention of stroke by anti- hypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the systolic hypertension in the elderly program (SHEP). SHEP cooperative research group.,» JAMA. 1991;265(24):3255–3264 .
  379. «Staessen JA, Fagard R, Thijs L, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The systolic hypertension in Europe (Syst-Eur) trial investigators. Lancet.,» 1997;350 (9080):757–764 .
  380. «Wang JG, Staessen JA, Gong L, et al. Chinese trial on isolated systolic hypertension in the elderly. Systolic hypertension in China (Syst-China) collaborative group. Arch Intern Med. 2000 Jan 24;160(2):211–220.».
  381. Kario K. et al. Efficacy and Safety of LCZ696, a First-in-Class Angiotensin Receptor Neprilysin Inhibitor, in Asian Patients With Hypertension/ Hypertension. 2014;63:698-705.
  382. «Perry HM Jr, Davis BR, Price TR, et al. Effect of treating isolated systolic hypertension on the risk of developing various types and subtypes of stroke: the Systolic Hypertension in the Elderly Program (SHEP). JAMA 2000; 284:465–471.».
  383. «Ogihara T, Saruta T, Rakugi H, et al. Target blood pressure for treatment of isolated systolic hypertension in the elderly: valsartan in elderly isolated systolic hypertension study. Hypertension 2010; 56:196–202.».
  384. «Sobieraj P, Lewandowski J, Sin ski M, Gaciong Z. Low on-treatment diastolic blood pressure and cardiovascular outcome: a posthoc analysis using NHLBI SPRINT Research Materials. Sci Rep 2019; 9:13070.».
  385. «Franklin SS, Chow VH, Mori AD, Wong ND. The significance of low DBP in US adults with isolated systolic hypertension. J Hypertens 2011; 29:1101–1108.».
  386. O’Rourke MF, Adji A. Guidelines on guidelines: focus on isolated systolic hypertension in youth. J Hypertens 2013;31:649–654..
  387. Yano Y, Stamler J, Garside DB, et al. Isolated systolic hypertension in young and middle-aged adults and 31-year risk for cardiovascular mortality: the Chicago Heart Association Detection Project in Industry study. JAmCollCardiol 2015;65:327–335..
  388. «Yu S, Zhang Y. The association between isolated systolic or diastolic hypertension and cardiovascular risk. J Hypertens 2021; 39:1552–1554.».
  389. «Romero CA, Tabares AH, Orias M. Is isolated diastolic hypertension an important phenotype? Curr Cardiol Rep 2021; 23:177.».
  390. «Xie K, Gao X, Bao L, et al. The different risk factors for isolated diastolic hypertension and isolated systolic hypertension: a national survey. BMC Public Health 2021; 21:1672».
  391. «China PEACE Collaborative Group §, China PEACE Collaborative Group. Prevalence, awareness, and treatment of isolated diastolic hypertension: insights from the China PEACE Million Persons Project. J Am Heart Assoc 2019; 8:e012954.».
  392. «Jacobsen AP, Al Rifai M, Arps K, et al. A cohort study and meta-analysis of isolated diastolic hypertension: searching for a threshold to guide treatment. Eur Heart J 2021; 42:2119–2129.».
  393. «Li FR, He Y, Yang HL, et al. Isolated systolic and diastolic hypertension by the 2017 American College of Cardiology/American Heart Association guidelines and risk of cardiovascular disease: a large prospective cohort study. J Hypertens 2021; 39:1594–1601».
  394. «Jacobsen AP, Al Rifai M, Arps K, et al. A cohort study and meta-analysis of isolated diastolic hypertension: searching for a threshold to guide treatment. Eur Heart J 2021; 42:2119–2129.».
  395. «Huang M, Long L, Tan L, et al. Isolated diastolic hypertension and risk of cardiovascular events: a systematic review and meta-analysis of cohort studies with 489,814 participants. Front Cardiovasc Med 2021; 8:810105.».
  396. «McEvoy JW, Yang WY, Thijs L, , et al., International Database on Ambulatory Blood Pressure in Relation to Cardiovascular Outcomes (IDACO) Investigators. Isolated diastolic hypertension in the IDACO study: an age-stratified analysis using 24-hourambulatory,» blood pressure measurements. Hypertension 2021; 78:1222–1231.
  397. Ogihara T, Saruta T, Rakugi H, et al.; COLM Investigators. Combination therapy of hypertension in the elderly: a subgroup analysis of the Combination of OLMesartan and a calcium channel blocker or diuretic in Japanese elderly hypertensive patients trial., Hypertens Res 2015;38:89-96..
  398. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure-lowering treatment on cardiovascular outcomes and mortality: 14 - effects of different classes of antihypertensive drugs in older and younger patients: overview and meta-analysis., J Hypertens. 2018 Aug;36(8):1637-1647. doi: 10.1097/HJH.0000000000001777.
  399. Corrao G, Mazzola P, Monzio Compagnoni M, et al. Antihypertensive medications, loop diuretics, and risk of hip fracturein the elderly: a population-based cohort study of 81,617 Italian patients newly treated between 2005 and 2009. Drugs Aging 2015;32:927–.
  400. Kjeldsen SE, Stenehjem A, Os I, et al. Treatment of high blood pressure in elderlyand octogenarians: European Society of Hypertension statement on blood pressure targets. Blood Press 2016;25:333–336..
  401. «Aparicio LS, Thijs L, Boggia J, et al. Defining thresholds for home blood pressure monitoring in octogenarians.Hypertension (Dallas, Tex: 1979) 2015; 66:865–873.».
  402. Zhang W et al. Trial of Intensive Blood-Pressure Control in Older Patients with Hypertension. N Engl J Med 2021; 385:1268-1279. DOI: 10.1056/NEJMoa2111437.
  403. «Ashworth DC, Maule SP, Stewart F, et al. Setting and techniques for monitoring blood pressure during pregnancy. Cochrane Database Syst Rev. 2020;8(8):CD012739».
  404. «Johnson S, Gordijn S, Damhuis S, et al; ISSHP. Diagnosis and Monitoring of White Coat Hypertension in Pregnancy: an ISSHP Consensus Delphi Procedure. Hypertension. 2022;79(5):993-1005».
  405. «Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists’ Task Force on Hypertension in Pregnancy. Obstet Gynecol. 2013 Nov;122(5):1122-1131. doi: 10.1097/01.AOG.0000437382.03963.88.».
  406. А. Tita, et al. Treatment for Mild Chronic Hypertension during Pregnancy. N Engl J Med 2022; 386:1781-1792. DOI: 10.1056/NEJMoa2201295.
  407. «Magee LA, Singer J, von Dadelszen P, Group CS. Less-tight versus tight control of hypertension in pregnancy. N Engl J Med 2015; 372:2367–2368.».
  408. Easterling T. et al. Oral antihypertensive regimens (nifedipine retard, labetalol, and methyldopa) for management of severe hypertension in pregnancy: an open-label, randomised controlled trial //The Lancet. – 2019. – Т. 394. – №. 10203. – С. 1011-1021..
  409. Weitz C. et al. Treatment of hypertension in pregnancy with methyldopa: a randomized double blind study //International Journal of Gynecology & Obstetrics. – 1987. – Т. 25. – №. 1. – С. 35-40..
  410. «Преэклампсия. Эклампсия. Отеки, протеинурия и гипертензивные расстройства во время беременности, в родах и послеродовом периоде : Клинические рекомендации / З. С. Ходжаева, Р. Г. Шмаков, Г. М. Савельева [и др.]. –,» – Москва : Министерство здравоохранения Российской Федерации, 2021. – 79 с..
  411. «Garovic VD, Dechend R, Easterling T, et al; Hypertension in Pregnancy: Diagnosis, Blood Pressure Goals, and Pharmacotherapy: A Scientific Statement From the American Heart Association. Hypertension. 2022;79(2):e21-e41. doi: 10.1161/HYP.0000000000000208».
  412. «КОМИТЕТ ЭКСПЕРТОВ РОССИЙСКОГО КАРДИОЛОГИЧЕСКОГО ОБЩЕСТВА (РКО). СЕКЦИЯ ЗАБОЛЕВАНИЯ СЕРДЕЧНО-СОСУДИСТОЙ СИСТЕМЫ У БЕРЕМЕННЫХ РЕКОМЕНДАЦИИ ПО ДИАГНОСТИКЕ И ЛЕЧЕНИЮ СЕРДЕЧНО-СОСУДИСТЫХ ЗАБОЛЕВАНИЙ ПРИ БЕРЕМЕННОСТИ 2018 НОВАЯ РЕДАКЦИЯ: ИЮЛЬ 2018 ГОДА,» (ТЕКСТ ДОСТУПЕН В ЭЛЕКТРОННОЙ ВЕРСИИ). Российский кардиологический журнал. 2018;(7):156-200. https://doi.org/10.15829/1560-4071-2018-7-156-200.
  413. «Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, et al 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy. Kardiol Pol. 2019;77(3):245-326. doi: 10.5603/KP.2019.0049.».
  414. «Cífková R. Hypertension in Pregnancy: A Diagnostic and Therapeutic Overview. High Blood Press Cardiovasc Prev. 2023;30(4):289-303».
  415. Rolnik DL, Wright D, Poon LC et al. Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia. N Engl J Med 2017;377:613–622..
  416. Roberge S., Nicolaides K., Demers S. et al. The role of aspirin dose on the prevention of preeclampsia and fetal growth restriction: systematic review and meta-analysis. Am J Obstet Gynecol. 2017;216(2):110–20.e6. DOI: 10.1016/j.ajog.2016.09.076..
  417. «Duley L, Meher S, Hunter KE, Seidler AL, Askie LM. Antiplatelet agents for preventing pre-eclampsia and its complications. Cochrane Database Syst Rev. 2019 Oct 30;2019(10):CD004659. doi: 10.1002/14651858.CD004659.pub3».
  418. Abalos E, Duley L, Steyn DW, Gialdini C. Antihypertensive drug therapy for mild to moderate hypertension during pregnancy. Cochrane Database of Systematic Reviews 2018, Issue 10. Art. No.: CD002252. DOI: 10.1002/14651858.CD002252.pub4..
  419. «Dan G Halpern et al., “Use of Medication for Cardiovascular Disease During Pregnancy: JACC State-of-the-Art Review,” J Am Coll Cardiol. 2019 Feb 5;73(4):457-476».
  420. «Magee LA, Brown MA, Hall DR, et al. The 2021 International Society for the Study of Hypertension in Pregnancy classification, diagnosis & management recommendations for international practice. Pregnancy Hypertens. 2022;27:148-169. doi: 10.1016/j.preghy.20».
  421. «Al Khalaf SY, O"Reilly ÉJ, Barrett PM, B Leite DF, Pawley LC, McCarthy FP, et al. Impact of chronic hypertension and antihypertensive treatment on adverse perinatal outcomes: systematic review and meta-analysis. J Am Heart Assoc. 2021;10(9):e018494.,» https://doi.org/10.1161/JAHA.120.018494..
  422. Kayser A, Beck E, Hoeltzenbein M, et al. Neonatal effects of intrauterine metoprolol/bisoprolol exposure during the second and third trimester: a cohort study with two comparison groups. J Hypertens. 2020;38(2):354–61., https://doi.org/10.1097/HJH.0000000000002256.
  423. Katsi, V., Papakonstantinou, I.P., Papazachou, O. et al. Beta-Blockers in Pregnancy: Clinical Update. Curr Hypertens Rep 25, 13–24 (2023). https://doi.org/10.1007/s11906-023-01234-8.
  424. «Tuimala R, Punnonen R, Kauppila E. Clonidine in the treatment of hypertension during pregnancy. Ann Chir Gynaecol Suppl. 1985;197:47-50”;».
  425. «Halpern DG, Weinberg CR, Pinnelas R, et al. Use of Medication for Cardiovascular Disease During Pregnancy: JACC State-of-the-Art Review. J Am Coll Cardiol. 2019;73(4):457-476. doi: 10.1016/j.jacc.2018.10.075».
  426. Williams B et al. 2018 Practice guidelines for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. Blood pressure 27.6 (2018): 314–340..
  427. «Fu, Jennifer, George Tomlinson, and Denice S. Feig. "Increased risk of major congenital malformations in early pregnancy use of angiotensin‐converting‐enzyme inhibitors and angiotensin‐receptor‐blockers: a meta‐analysis.",» Diabetes/Metabolism Research and Reviews 37.8 (2021): e3453..
  428. «Cooper WO, Hernandez-Diaz S, Arbogast PG, Dudley JA, Dyer S, Gideon PS, Hall K, Ray WA. Major congenital malformations after first-trimester exposure to ACE inhibitors. N Engl J Med. 2006 Jun 8;354(23):2443-51. doi: 10.1056/NEJMoa055202.».
  429. «Society for Maternal-Fetal Medicine; Publications Committee. Electronic address: pubs@smfm.org. Society for Maternal-Fetal Medicine Statement: Antihypertensive therapy for mild chronic hypertension in pregnancy-The Chronic Hypertension and Pregnancy trial,» Am J Obstet Gynecol. 2022;227(2):B24-B27. doi: 10.1016/j.ajog.2022.04.011.
  430. « Halpern DG, Weinberg CR, Pinnelas R, et al. Use of Medication for Cardiovascular Disease During Pregnancy: JACC State-of-the-Art Review. J Am Coll Cardiol. 2019;73(4):457-476. doi: 10.1016/j.jacc.2018.10.075».
  431. Curtis KM et al. Combined oral contraceptive use among women with hypertension: a systematic review. Contraception 73.2 (2006):179–188..
  432. Lubianca JN, Moreira LB, Gus M, Fuchs FD. Stopping oral contraceptives: an effective blood pressure-lowering intervention in women with hypertension. J Hum Hypertens 2005;19:451–455..
  433. Chasan-Taber L, Willett WC, Manson JE, et al. Prospective study of oral contraceptives and hypertension among women in the United States. Circulation 1996;94:483–489..
  434. Dong W, Colhoun HM, Poulter NR. Blood pressure in women using oral contraceptives: results from the Health Survey for England 1994. J Hypertens 1997;15:1063–1068..
  435. Gillum LA, Mamidipudi SK, Johnston SC. Ischemic stroke risk with oral contraceptives: a meta-analysis. JAMA 2000;284:72–78..
  436. World Health Organization. Medical eligibility criteria for contraceptive use. Third edition, 2004. http://apps.who.int/iris/bitstream/10665/42907/1/ 9241562668.pdf (date accessed June 28th 2018)..
  437. «КР МЗ РФ 117 «Менопауза и климактерическое состояние у женщины» https://cr.minzdrav.gov.ru/recomend/117_2, стр.24».
  438. La Torre A, Giupponi G, Duffy D, et al. Sexual dysfunction related to drugs: a critical review. Part IV: cardiovascular drugs.Pharmacopsychiatry 2015;48:1–6..
  439. Pickering TG, Shepherd AM, Puddey I, et al. Sildenafil citrate for erectile dysfunction in men receiving multiple antihypertensive agents: a randomized controlled trial..
  440. Jain M, Townsend RR. Chemotherapy agents and hypertension: a focus on angiogenesis blockade. Curr Hypertens Rep 2007;9:320–328..
  441. Hassen LJ, Lenihan DJ, Baliga RR. Hypertension in the Cardio-Oncology Clinic. Heart Fail Clin. 2019 Oct;15(4):487-495. doi: 10.1016/j.hfc.2019.06.010. PMID: 31472884..
  442. «van Dorst DCH, Dobbin SJH, Neves KB, et al. Hypertension and prohypertensive antineoplastic therapies in cancer patients. Circ Res 2021; 128:1040–1061».
  443. «Kim CS, Han KD, Choi HS, et al. Association of hypertension and blood pressure with kidney cancer risk: a nationwide population-based cohort study. Hypertension 2020; 75:1439–1446.».
  444. «Alcala K, Mariosa D, Smith-Byrne K, et al. The relationship between blood pressure and risk of renal cell carcinoma. Int J Epidemiol 2022; 51:1317–1327.».
  445. «Weikert S, Boeing H, Pischon T, et al. Blood pressure and risk of renal cell carcinoma in the European prospective investigation into cancer and nutrition. Am J Epidemiol 2008; 167:438–446».
  446. «Cohen JB, Brown NJ, Brown SA, et al. Cancer therapy-related hypertension: a scientific statement from the American Heart Association. Hypertension 2023; 80:e46–e57.».
  447. «Tlemsani C, Mir O, Boudou-Rouquette P, Huillard O, Maley K, Ropert S, et al. Posterior reversible encephalopathy syndrome induced by anti-VEGF agents. Target Oncol 2011; 6:253–258».
  448. «Ferrara N, Adamis AP. Ten years of antivascular endothelial growth factor therapy. Nat Rev Drug Discov 2016; 15:385–403.».
  449. «Versmissen J, Mirabito Colafella KM, Koolen SLW, et al. Vascular cardio-oncology: vascular endothelial growth factor inhibitors and hypertension. Cardiovasc Res 2019; 115:904–914.».
  450. «Webster K, Fishburn S, Maresh M, et al. Diagnosis and management of hypertension in pregnancy: summary of updated NICE guidance. BMJ 2019; 366:l5119.».
  451. «Garovic VD, Dechend R, Easterling T, et al., American Heart Association Council on Hypertension; Council on the Kidney in Cardiovascular Disease, Kidney in Heart Disease Science Committee; Council on Arteriosclerosis, Thrombosis and Vascular Biology;,» Council on Lifestyle and Cardiometabolic Health; Council on Peripheral Vascular Disease; and Stroke Council. Hypertension in pregnancy: diagnosis, blood pressure goals, and pharmacotherapy: a scientific statement from the American Heart Association. , Hypertension 2022; 79:e21–e41..
  452. «Weikert S, Boeing H, Pischon T, et al. Blood pressure and risk of renal cell carcinoma in the European prospective investigation into cancer and nutrition. Am J Epidemiol 2008; 167:438–446».
  453. «Moslehi JJ. Cardiovascular toxic effects of targeted cancer therapies. N Engl J Med 2016; 375:1457–1467.».
  454. «Azizi M, Chedid A, Oudard S. Home blood-pressure monitoring in patients receiving sunitinib. N Engl J Med 2008; 358:95–97.».
  455. «Baek Moller N, Budolfsen C, Grimm D, et al. Drug-induced hypertension caused by multikinase inhibitors (sorafenib, sunitinib, lenvatinib and axitinib) in renal cell carcinoma treatment. Int J Mol Sci 2019; 20:4712.».
  456. Lyon AR, López-Fernández T, Couch LS, Asteggiano R, Aznar MC,et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and, and the International Cardio-Oncology Society (IC-OS). Eur Heart J. 2022 Aug 26:ehac244. doi: 10.1093/eurheartj/ehac244. .
  457. «Campia U, Moslehi JJ, Amiri-Kordestani L, et al. Cardio-oncology: vascular and metabolic perspectives: a scientific statement from the American Heart Association. Circulation 2019; 139:e579–e602.».
  458. «Eremina V, Jefferson JA, Kowalewska J, et al. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med 358:1129–1136».
  459. «van Dorst DCH, van Doorn L, Mirabito Colafella KM, et al. Cardiovascular toxicity of angiogenesis inhibitors and immune checkpoint inhibitors: synergistic antitumour effects at the cost of increased cardiovascular risk? Clin Sci (Lond) 2021; 135:1649–1668».
  460. «Roviello G, Sigala S, Danesi R, et al. Incidence and relative risk of adverse events of special interest in patients withcastration resistant prostate cancer treated with CYP-17 inhibitors: a meta-analysis of published trials. Crit Rev Oncol Hematol 2016;,» 101:12–20..
  461. «Attard G, Reid AH, Auchus RJ, et al. Clinical and biochemical consequences of CYP17A1 inhibition with abiraterone given with and without exogenous glucocorticoids in castrate men with advanced prostate cancer. J Clin Endocrinol Metab 2012;97:507 – 516».
  462. «Izzedine H, Cluzel P, Deray G. Renal radiation-induced arterial stenosis. Kidney Int 2007; 71:1188.y».
  463. «Biaggioni I, Shibao CA, Diedrich A et al. Blood pressure management in afferent baroreflex failure: JACC Review Topic of the Week. J Am Coll Cardiol 2019; 74:2939–2947.».
  464. «Weintraub NL, Jones WK, Manka D. Understanding radiation-induced vascular disease. J Am Coll Cardiol 2010; 55:1237–1239».
  465. Maitland ML, Bakris GL, Black HR, et al. Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors. J Natl Cancer Inst. 2010;102:596–604..
  466. «Herrmann J, Lenihan D, Armenian S, et al. Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement. Eur Heart J 2022; 43:280–299.».
  467. Chang HM, Okwuosa TM, Scarabelli T, et al. Cardiovascular complications of cancer therapy: best practices in diagnosis, prevention, and management: Part 2. J Am Coll Cardiol 2017;70:2552–2565..
  468. Milan A, Puglisi E, Ferrari L et al. Arterial hypertension and cancer. Int J Cancer 2014;134:2269–2277..
  469. Penttilä P, Rautiola J, Poussa T, Peltola K, Bono P. Angiotensin inhibitors as treat- ment of sunitinib/pazopanib-induced hypertension in metastatic renal cell carcin- oma. Clin Genitourin Cancer 2017;15:384–390.e3. doi: 10.1016/j.clgc.2016.12.016..
  470. Izzedine H, Derosa L, Le Teuff G, Albiges L, Escudier B. Hypertension and angioten- sin system inhibitors: impact on outcome in sunitinib-treated patients for metastat- ic renal cell carcinoma. Ann Oncol 2015;26:1128–1133. doi: 10.1093/annonc/mdv147.
  471. McKay RR, Rodriguez GE, Lin X, Kaymakcalan MD, Hamnvik OPR, Sabbisetti VS, et al. Angiotensin system inhibitors and survival outcomes in patients with meta- static renal cell carcinoma. Clin Cancer Res 2015;21:2471–2479. doi: 10.1158/1078-0432.CCR-14-2.
  472. «Li, X. Y., Sun, J. F., & Hu, S. Q. (2017). The renin-angiotensin system blockers as adjunctive therapy for cancer: a meta-analysis of survival outcome. European Review for Medical & Pharmacological Sciences, 21(6).».
  473. «Versmissen J, Mirabito Colafella KM, Koolen SLW, Danser AHJ. Vascular cardio-oncology: vascular endothelial growth factor inhibitors and hypertension. Cardiovasc Res 2019; 115:904–914».
  474. «Steingart RM, Bakris GL, Chen HX, Chen MH, Force T, Ivy SP, et al. Management of cardiac toxicity in patients receiving vascular endothelial growth factor signaling pathway inhibitors. Am Heart J 2012; 163:156–163».
  475. «Beavers CJ, Rodgers JE, Bagnola AJ et al., American Heart Association Clinical Pharmacology Committee and Cardio-Oncology Committee of the Council on Clinical Cardiology and Council on Genomic and Precision Medicine; and the Council on Peripheral Vascular,» Disease. Cardio-oncology drug interactions: a scientific statement from the American Heart Association. Circulation 2022; 145:e811–e838..
  476. «van Dorst DCH, Kabadayi S, Oomen-de Hoop E, et al. Treatment and implications of vascular endothelial growth factor inhibitor-induced blood pressure rise: a clinical cohort study. J Am Heart Assoc 2023; 12:e028050.».
  477. «van Doorn L, Visser WJ, van Dorst DCH, et al. Dietary sodium restriction prevents vascular endothelial growth factor inhibitor-induced hypertension. Br J Cancer 2023; 128:354–362.».
  478. «Gibson TM, Li Z, Green DM, , et al. Blood pressure status in adult survivors of childhood cancer: a report from the St. Jude Lifetime Cohort Study. Cancer Epidemiol Biomarkers Prev 2017; 26:1705–1713.».
  479. Cannon C. P. et al. Ezetimibe added to statin therapy after acute coronary syndromes //New England Journal of Medicine. – 2015. – Т. 372. – №. 25. – С. 2387-2397..
  480. Trialists C. T. et al. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174 000 participants in 27 randomised trials //The Lancet. – 2015. – Т. 385. – №. 9976. – С. 1397-1405..
  481. Sabatine M. S. et al. Evolocumab and clinical outcomes in patients with cardiovascular disease //New England Journal of Medicine. – 2017. – Т. 376. – №. 18. – С. 1713-1722..
  482. Jukema J. W. et al. ODYSSEY OUTCOMES Committees and Investigators. Alirocumab in patients with polyvascular disease and recent acute coronary syndrome: ODYSSEY OUTCOMES trial //J Am Coll Cardiol. – 2019. – Т. 74. – №. 9. – С. 1167-1176..
  483. Trialists C. T. et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials //The Lancet. – 2012. – Т. 380. – №. 9841. – С. 581-590..
  484. «Jukema JW, et al. Alirocumab in Patients With Polyvascular Disease and Recent Acute Coronary Syndrome: ODYSSEY OUTCOMES Trial. J Am Coll Cardiol. 2019 Sep 3;74(9):1167-1176. doi: 10.1016/j.jacc.2019.03.013. Epub 2019 Mar 18. PMID: 30898609.».
  485. «Vallejo-Vaz, A. J., Ray, K. K., Ginsberg, H. N., Davidson, M. H., Eckel, R. H., Lee, L. V., ... & Cannon, C. P. (2019). Associations between lower levels of low-density lipoprotein cholesterol and cardiovascular events in very high-risk patients:,» pooled analysis of nine ODYSSEY trials of alirocumab versus control. Atherosclerosis, 288, 85-93..
  486. Yusuf S, Lonn E, Pais P, Bosch J, López-Jaramillo Pet al; HOPE-3 Investigators. Blood-Pressure and Cholesterol Lowering in Persons without Cardiovascular Disease. N Engl J Med. 2016 May 26;374(21):2032-43. doi: 10.1056/NEJMoa1600177.
  487. Sever PS, Dahlof B, Poulter NR, et al. ASCOT Investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than- average cholesterol concentrations, in the Anglo-Scandinavian Cardiac, Outcomes Trial — Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003;361:1149–1158. .
  488. «Collins R, Reith C, Emberson J, et al. Interpretation of the evidence for the efficacy and safety of statin therapy.».
  489. «Bhatt DL, Steg PG, Miller M, et al., REDUCE-IT Investigators. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med 2019; 380:11–22.».
  490. «Nicholls SJ, Lincoff AM, Garcia M,, et al. Effect of high-dose omega-3 fatty acids vs corn oil on major adverse cardiovascular events in patients at high cardiovascular risk: the STRENGTH randomized clinical trial. JAMA 2020; 324:2268–2280.».
  491. Joseph P, Roshandel G, Gao P, Pais P, Lonn E, et al; Polypill Trialists" Collaboration. Fixed-dose combination therapies with and without aspirin for primary prevention of cardiovascular disease: an individual participant data meta-analysis. Lancet. 2021, Sep 25;398(10306):1133-1146. doi: 10.1016/S0140-6736(21)01827-4. .
  492. Castellano JM, Pocock SJ, Bhatt DL, Quesada AJ, Owen R, et al; SECURE Investigators. Polypill Strategy in Secondary Cardiovascular Prevention. N Engl J Med. 2022 Sep 15;387(11):967-977. doi: 10.1056/NEJMoa2208275..
  493. «Coca A, Agabiti-Rosei E, Cifkova R, et al. The polypill in cardiovascular prevention: evidence, limitations and perspective - position paper of the European Society of Hypertension. J Hypertens 2017; 35:1546–1553.».
  494. Lip GY, Felmeden DC, Dwivedi G. Antiplatelet agents and anticoagulants for hypertension. Cochrane Database Syst Rev 2011;12:CD003186.
  495. «Shantsila E, Kozieł-Siołkowska M, Lip GY. Antiplatelet agents and anticoagulants for hypertension. Cochrane Database Syst Rev. 2022 Jul 28;7:CD003186. doi: 10.1002/14651858.CD003186.pub4. PMID: 35900898.».
  496. «ASCEND Study Collaborative Group, Bowman L, Mafham M, Wallendszus K, et al. Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus. N Engl J Med 2018;379:15291539.».
  497. «Seidu S, Kunutsor SK, Sesso HD, Gaziano JM, Buring JE, Roncaglioni MC, Khunti K. Aspirin has potential benefits for primary prevention of cardiovascular outcomes in diabetes:,» updated literature-based and individual participant data meta-analyses of randomized controlled trials. Cardiovasc Diabetol 2019;18:70.
  498. «Бойцов С.А., Погосова Н.В., Аншелес А.А., и соавт. Кардиоваскулярная профилактика 2022. Российские национальные рекомендации. Российский кардиологический журнал. 2023;28(5):5452. doi:10.15829/1560-4071-2023-5452.».
  499. van den Born BJ, Lip GYH, Brguljan-Hitij J, et al. ESC Council on hypertension position document on the management of hypertensive emergencies. Eur Heart J Cardiovasc Pharmacotherapy 2018..
  500. Vaughan CJ, Delanty N. Hypertensive emergencies. Lancet 2000;356:411–417..
  501. Chester EM, Agamanolis DP, Banker BQ, Victor M. Hypertensive encephalopathy: a clinicopathologic study of 20 cases. Neurology 1978;28:928–939..
  502. van den Born BJ, Koopmans RP, Groeneveld JO, van Montfrans GA. Ethnic disparities in the incidence, presentation and complications of malignant hypertension. J Hypertens 2006;24:2299–2304.
  503. Cremer A, Amraoui F, Lip GY, et al. From malignant hypertension to hypertension-MOD: a modern definition for an old but still dangerous emergency. J Hum Hypertens 2016;30:463–466..
  504. Pinna G, Pascale C, Fornengo P, et al. Hospital admissions for hypertensive crisis in the emergency departments: a large multicenter Italian study. PLoS One 2014;9:e93542..
  505. van den Born BJ, Lowenberg EC, van der Hoeven NV, et al. Endothelial dysfunction, platelet activation, thrombogenesis and fibrinolysis in patients with hypertensive crisis. J Hypertens 2011;29:922–927..
  506. «Grassi D, O’Flaherty M, Pellizzari M, et al. Hypertensive urgencies in the emergency department: evaluating blood pressure response to rest and to antihypertensive drugs with different profiles. J Clin Hypertens (Greenwich) 2008;10:662–667.».
  507. «Perez MI, Musini VM. Pharmacological interventions for hypertensive emergencies: a Cochrane systematic review. J Hum Hypertens 2008;22:596–607.».
  508. «Grossman A, Messerli FH, Grossman E. Drug induced hypertension — An unappreciated cause of secondary hypertension. Eur J Pharmacol 2015;763:15–22.».
  509. «Приказ Министерства здравоохранения РФ от 31 июля 2020 г. N 778н "О Порядке организации медицинской реабилитации взрослых" Зарегистрировано в Минюсте РФ 25 сентября 2020 г. Регистрационный № 60039 https://www.garant.ru/products/ipo/prime/doc/74581688/».
  510. «Cicero A.F.G., Grassi D., Tocci G., et al. Nutrients and nutraceuticals for the management of high normal blood pressure: an evidence-based consensus document. High Blood Press Cardiovasc Prev. 2019;26:9–25.».
  511. «Global Burden of Disease Risk Factor Collaborators. Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990– 2016: a systematic analysis for the,» Global Burden of Disease Study 2016. Lancet. 2017;390:1345–1422..
  512. «Lopez S.A.L. Effectiveness of the mindfulness-based stress reduction program on blood pressure: a systematic review of literature. Worldviews Evid Based Nurs. 2018;15:344–352.».
  513. «Ambrosetti M., Abreu A., Corrà U., et al. Secondary prevention through comprehensive cardiovascular rehabilitation: From knowledge to implementation. 2020 update. A position paper from the Secondary Prevention and Rehabilitation Section of the,» European Association of Preventive Cardiology. European Journal of Preventive Cardiology. 2020; 28:460-495. doi: 10.1177/2047487320913379.PMID: 32223332..
  514. «Juocevicius A., Oral A., Lukmann A, et al. Evidence-based position paper on Physical and Rehabilitation Medicine (PRM) professional practice for people with cardiovascular conditions. The European PRM position (UEMS PRM Section).,» European Journal of Physical and Rehabilitation Medicine. 2018;54(4):634-43. doi: 10.23736/S1973-9087.18.05310-8..
  515. «Иванова Г.Е., Мельникова Е.В., Шмонин А.А., и др. Применение международной классификации функционирования в процессе медицинской реабилитации. Вестник восстановительной медицины. 2018. № 6 (88). С. 2-77. eLIBRARY ID: 36486374.».
  516. «Barber S., Thornicroft G. Reducing the Mortality Gap in People With Severe Mental Disorders: The Role of Lifestyle Psychosocial Interventions. Front Psychiatry. 2018;9:463.».
  517. «Hanssen H., Boardman H., Deiseroth A., et al. Personalized exercise prescription in the prevention and treatment of arterial hypertension: a Consensus Document from the European Association of Preventive Cardiology (EAPC) and the ESC Council on Hypertensi».
  518. «Kraus W.E., Powell K.E., Haskell W.L., et al. 2018 Physical Activity Guidelines Advisory Committee. Physical Activity, All-Cause and Cardiovascular Mortality, and Cardiovascular Disease. Med Sci Sports Exerc. 2019;51:1270-1228.».
  519. «Pescatello L.S., Buchner D.M., Jakicic J.M., et al. for the 2018 Physical activity guidelines advisory committee. Physical Activity to Prevent and Treat Hypertension: A Systematic Review. Med.Sci. Sports Exerc.. 2019; 51(6): 1314–1323.».
  520. «Semlitsch T. et al. Increasing physical activity for the treatment of hypertension: a systematic review and meta-analysis. Sports medicine. 2013; 43(10): 1009- 1023.».
  521. «Fletcher G.F., Ades P.A., Kligfield P., et al. American Heart Association Exercise, Cardiac Rehabilitation, and Prevention Committee of the Council on Clinical Cardiology, Council on Nutrition, Physical Activity and Metabolism, Council on,» Cardiovascular and Stroke Nursing, and Council on Epidemiology and Prevention. Exercise standards for testing and training: a scientific statement from the American Heart Association. Circulation. 2013;128(8):873-934. doi:10.1161/CIR.0b013e31829b5b44. .
  522. «Lu Z., Song Y., Chen H., et al. A Mixed Comparisons of Aerobic Training With Different Volumes and Intensities of Physical Exercise in Patients With Hypertension: A Systematic Review and Network Meta-Analysis. Cardiovasc. Med. 2022;».
  523. «Whelton S.P., Chin A., Xin X., et al. Effect of aerobic exercise on blood pressure: a meta-analysis of randomized, controlled trials. Ann Intern Med. 2002;136:493–503.».
  524. «Inder J.D., Carlson D.J., Dieberg G., et al. Isometric exercise training for blood pressure management: a systematic review and meta-analysis to optimize benefit. Hypertens Res. 2016;39:88–94.».
  525. «Borg G. Psychophysical scaling with applications in physical work and the perception of exertion. Scand J Work Environ Health. 1990;16(Suppl 1):55–58.».
  526. «Duan Y, Xie Z, Dong F, et al. Effectiveness of home blood pressure telemonitoring: a systematic review and meta-analysis of randomised controlled studies. J Hum Hypertens. 2017;31:427–437.».
  527. «Bray EP, Holder R, Mant J, McManus RJ. Does self-monitoring reduce bloodpressure? Meta-analysis with meta-regression of randomized controlled trials. . Ann Med 2010;42:371–386.».
  528. «Niiranen TJ, Hanninen MR, Johansson J, et al. Home-measuredblood pressure is a stronger predictor of cardiovascular risk than office bloodpressure: the Finn-Home study. Hypertension 2010;55:1346–1351.».
  529. «Приказ Министерства здравоохранения Российской Федерации от 15.03.2022 № 168н "Об утверждении порядка проведения диспансерного наблюдения за взрослыми" (Зарегистрирован 21.04.2022 № 68288)».
  530. «Лещук, Т. Ю. (2015). Организационно-профилактические мероприятия по выявлению скрытых признаков артериальной гипертензии. CardioСоматика, (S1), 58-58.».
  531. «Усманова, Х. С. (2024, February). РЕНТГЕНОЛОГИЧЕСКИЕ ИЗМЕНЕНИЯ СЕРДЦА ПРИ АРТЕРИАЛЬНОЙ ГИПЕРТЕНЗИИ. In Proceedings of International Conference on Modern Science and Scientific Studies (Vol. 3, No. 2, pp. 317-320).».
  532. «Julius S, Nesbitt SD, Egan BM, et al. Trial of Preventing Hypertension Study Investigators. Feasibility of treating prehypertension with an angiotensin-receptor blocker. N Engl J Med 2006;354:1685–1697.».
  533. «Cook NR, Cutler JA, Obarzanek E et al. Long term effects of dietary sodium reduction on cardiovascular disease outcomes: observational follow-up of the trials of hypertension prevention (TOHP). BMJ 2007;334:885–888.».
  534. «Fahey T., Schroeder K., Ebrahim S. Educational and organisational interventions used to improve the management of hypertension in primary care: a systematic review //Br J Gen Pract. – 2005. – Т. 55. – №. 520. – С. 875-882.».
  535. «Glynn L. G. et al. Interventions used to improve control of blood pressure in patients with hypertension //Cochrane database of systematic reviews. – 2010. – №. 3».
  536. «Birtwhistle RV, Godwin MS, Delva MD, et al. Randomised equivalence trial comparing three month and six month follow up of patients with hypertension by family practitioners. BMJ.2004;328:204.».
  537. «Omboni S, Gazzola T, Carabelli G, Parati G. Clinical usefulness and cost effectiveness of home blood pressure telemonitoring: meta-analysis of randomized controlled studies. J Hypertens. 2013;31:455-468.».
  538. «Omboni S, Ferrari R. The role of telemedicine in hypertension management: focus on blood pressure telemonitoring. Curr Hypertens Rep. 2015;17:535.».
  539. «Ткачева О.Н., Рунихина Н.К., Остапенко В.С., Шарашкина Н.В., Мхитарян Э.А., Онучина Ю.С., Лысенков С.Н. Валидация опросника для скрининга синдрома старческой астении в амбулаторной практике. Успехи геронтологии. 2017. Т. 30. № 2. С. 236-242.».

Для продолжения работы требуется Регистрация
На предыдущую страницу

Предыдущая страница

Следующая страница

На следующую страницу
Список литературы
На предыдущую главу Предыдущая глава
оглавление
Следующая глава На следующую главу

Оглавление

Данный блок поддерживает скрол*